Tokushima University / Educator and Researcher Directory --- Satou, Seidai

Field of Study

Subject of Study

Book / Paper

Book:

1.	Seidai Satou and Yasuhiko Nishioka : 進行性線維化を伴う間質性肺疾患の診断と治療, Nankodo, Mar. 2023.
2.	Seidai Satou and Yasuhiko Nishioka : 特発性間質性肺炎, NIPPONRINSHOSHA Co.,Ltd., Tokyo, Oct. 2021.
3.	Seidai Satou and Yasuhiko Nishioka : 呼吸細気管支炎を伴う間質性肺疾患(RB-ILD), 株式会社中外医学社, Tokyo, Aug. 2021.
4.	Seidai Satou and Yasuhiko Nishioka : 非特異性間質性肺炎(NSIP), 株式会社中外医学社, Tokyo, Aug. 2021.
5.	Seidai Satou and Yasuhiko Nishioka : 特発性器質化肺炎(COP/BOOP), Nankodo, Tokyo, Mar. 2021.
6.	Seidai Satou and Yasuhiko Nishioka : Nintedanibの使い方と副作用対策, Nankodo, Tokyo, Jun. 2020.
7.	Seidai Satou and Yasuhiko Nishioka : サルコイドーシス, IGAKU-SHOIN Ltd.Tokyo,Japan, Mar. 2020.
8.	Seidai Satou and Yasuhiko Nishioka : 特発性間質性肺炎(その他の非特異性間質性肺炎，器質化肺炎), Japan Medkal Journal, Jul. 2019.
9.	Seidai Satou and Yasuhiko Nishioka : 間質性肺炎・過敏性肺炎, NANZANDO Co.,Ltd., May 2019.
10.	Seidai Satou and Yasuhiko Nishioka : 細胞生物学，分子病態, 2015.

Academic Paper (Judged Full Paper):

1.	Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi, Thi Na Nguyen, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Satou, Masaki Hanibuchi, Tsutomu Shinohara, Hiroshi Nokihara and Yasuhiko Nishioka : Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies., Journal of Thoracic Oncology, Vol.15, No.5, 369-378, 2023. (Summary) Our findings indicate that fluoropyrimidine can be an immunologically optimal partner of ICIs through the induction of ICD for thoracic malignancies. (Keyword) Humans / Animals / Mice / Carcinoma, Non-Small-Cell Lung / Immune Checkpoint Inhibitors / CD8-Positive T-Lymphocytes / Platinum / Immunogenic Cell Death / Lung Neoplasms / Pemetrexed / Antimetabolites / Cell Line, Tumor / Taxoids / Fluorouracil / Adenosine Triphosphate / Tumor Microenvironment (Link to Publication Site) ● Publication site (DOI): 10.1111/1759-7714.15200 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38146645 ● Search Scopus @ Elsevier (PMID): 38146645 ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.15200 (DOI: 10.1111/1759-7714.15200, PubMed: 38146645)
2.	Hiroto Yoneda, Atsushi Mitsuhashi, Aito Yoshida, Hirokazu Ogino, Satoshi Itakura, Thi Na Nguyen, Hiroshi Nokihara, Seidai Satou, Tsutomu Shinohara, Masaki Hanibuchi, Shinji Abe, K Mika Kaneko, Yukinari Kato and Yasuhiko Nishioka : Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells., Cancer Science, Vol.115, No.2, 357-368, 2023. (Summary) -f enhanced the antitumor effects of CTLA-4 blockade. Combination therapy with anti-PDPN Ab and anti-CTLA-4 Ab increased tumor-infiltrating natural killer (NK) cells. The depletion of NK cells inhibited the synergistic effects of PMab-1-mG (Keyword) Rats / Mice / Animals / Cricetinae / Mesothelioma, Malignant / Antibodies, Monoclonal / CTLA-4 Antigen / Membrane Glycoproteins / Mesothelioma / Killer Cells, Natural / Cricetulus / CHO Cells (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.16046 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38148492 ● Search Scopus @ Elsevier (PMID): 38148492 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.16046 (DOI: 10.1111/cas.16046, PubMed: 38148492)
3.	Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Kozo Kagawa, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka : A novel BRD4 degrader, ARV-825, attenuates lung fibrosis through senolysis and antifibrotic effect., Respiratory Investigation, Vol.61, No.6, 781-792, 2023. (Summary) These results suggest that ARV825 may impact the progressive and irreversible course of fibrotic lung diseases. (Keyword) Humans / Mice / Animals / Nuclear Proteins / Senotherapeutics / Transcription Factors / Lung / Idiopathic Pulmonary Fibrosis / Bleomycin / Collagen / Mice, Inbred C57BL / Cell Cycle Proteins (Link to Publication Site) ● Publication site (DOI): 10.1016/j.resinv.2023.08.003 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37741093 ● Search Scopus @ Elsevier (PMID): 37741093 ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2023.08.003 (DOI: 10.1016/j.resinv.2023.08.003, PubMed: 37741093)
4.	Yohei Yabuki, Masaki Hanibuchi, Eiji Takeuchi, Takashi Haku, Takanori Kanematsu, Naoki Nishimura, Yuko Toyoda, Atsushi Mitsuhashi, Kenji Otsuka, Seidai Satou, Hisatsugu Goto, Hiroto Yoneda, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka : A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer., Thoracic cancer, Vol.14, No.32, 3232-3239, 2023. (Summary) Combination chemotherapy with PEM plus Bev in elderly patients with previously untreated advanced non-squamous NSCLC exhibited favorable antitumor activity and tolerability, suggesting that a combination of PEM plus Bev might be a promising treatment option for this population. (Keyword) Humans / Aged / Aged, 80 and over / Carcinoma, Non-Small-Cell Lung / Pemetrexed / Bevacizumab / Lung Neoplasms / Treatment Outcome / Antineoplastic Combined Chemotherapy Protocols (Link to Publication Site) ● Publication site (DOI): 10.1111/1759-7714.15115 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37718463 ● Search Scopus @ Elsevier (PMID): 37718463 ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.15115 (DOI: 10.1111/1759-7714.15115, PubMed: 37718463)
5.	Saki Harada, Takeshi Imakura, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : A case of successful treatment with eltrombopag for severe immune-related thrombocytopenia induced by atezolizumab:Case report., The journal of medical investigation : JMI, Vol.70, No.3.4, 516-520, 2023. (Summary) Immune checkpoint inhibitors (ICIs) have shown impressive anti-tumor effects against multiple types of malignancies. Among the wide variety of immune-related adverse events (irAEs), immune-related thrombocytopenia (ITP) is relatively rare but often clinically significant and life-threatening. However, the appropriate treatment for severe ITP has not been determined. We herein report an 82-year-old male patient with non-small-cell lung cancer who developed severe ITP three weeks after starting the third course of atezolizumab. The initial combination therapy with high-dose prednisolone, intravenous immunoglobulin and platelet transfusion was ineffective. However, additional treatment with eltrombopag, a thrombopoietin receptor agonist, resulted in remarkable improvement in the thrombocytopenia. J. Med. Invest. 70 : 516-520, August, 2023. (Keyword) Male / Humans / Aged, 80 and over / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Thrombocytopenia / Purpura, Thrombocytopenic, Idiopathic (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.516 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37940542 ● Search Scopus @ Elsevier (PMID): 37940542 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.516 (DOI: 10.2152/jmi.70.516, PubMed: 37940542)
6.	Hiroki Takahashi, Hirokazu Ogino, Hiroki Bando, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : FoundationOne CDx detected an uncovered variant of epidermal growth factor receptor exon 19 deletion by Oncomine Dx target test in a patient with lung adenocarcinoma., Respiratory Medicine Case Reports, Vol.45, 101893, 2023. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.rmcr.2023.101893 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37485237 ● Search Scopus @ Elsevier (PMID): 37485237 ● Search Scopus @ Elsevier (DOI): 10.1016/j.rmcr.2023.101893 (DOI: 10.1016/j.rmcr.2023.101893, PubMed: 37485237)
7.	Takeshi Imakura, Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis., Respiratory Research, Vol.24, No.1, 2023. (Summary) These findings suggest that targeting PLK1 may be a novel therapeutic approach for pulmonary fibrosis by inhibiting lung fibroblast proliferation without affecting lung epithelial cells. In addition, while in silico screening is useful, it is essential to fully determine the biological activities of candidates by wet-lab validation studies. (Keyword) Mice / Animals / Drug Repositioning / Thiophenes / Benzimidazoles / Lung / Idiopathic Pulmonary Fibrosis / Fibroblasts / Bleomycin (Tokushima University Institutional Repository) ● Metadata: 119057 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12931-023-02446-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37269004 ● Search Scopus @ Elsevier (PMID): 37269004 ● Search Scopus @ Elsevier (DOI): 10.1186/s12931-023-02446-x (Tokushima University Institutional Repository: 119057, DOI: 10.1186/s12931-023-02446-x, PubMed: 37269004)
8.	Yasuhiko Nishioka, Sakae Homma, Takashi Ogura, Seidai Satou, Naoki Arai, Keisuke Tomii, Koichiro Kamio, Susumu Sakamoto, Yasunari Miyazaki, Hiromi Tomioka, Shu Hisata, Tomohiro Handa and Arata Azuma : Exploratory phase 2 study of the novel oral multi-kinase inhibitor TAS-115 in patients with idiopathic pulmonary fibrosis., Respiratory Investigation, Vol.61, No.4, 498-507, 2023. (Summary) Japic-Clinical Trials Information, JapicCTI-183898 (first registered: March 15, 2018). (Link to Publication Site) ● Publication site (DOI): 10.1016/j.resinv.2023.04.008 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37263115 ● Search Scopus @ Elsevier (PMID): 37263115 ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2023.04.008 (DOI: 10.1016/j.resinv.2023.04.008, PubMed: 37263115)
9.	Masaki Hanibuchi, Atsushi Mitsuhashi, Atsuro Saijo, Tatsuya Kajimoto, Seidai Satou, Tetsuya Kitagawa and Yasuhiko Nishioka : A case of atopic cough with aphonia showed a prominent response to a histamine H1 receptor antagonist., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 281-284, 2023. (Summary) -RA, a diagnosis of AC was made. To the best of our knowledge, this is the first report of an AC patient who presented severe cough with aphonia. J. Med. Invest. 70 : 281-284, February, 2023. (Keyword) adult / female / Humans / Aphonia / Cough / Histamine H1 Antagonists (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.281 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164735 ● Search Scopus @ Elsevier (PMID): 37164735 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.281 (DOI: 10.2152/jmi.70.281, PubMed: 37164735)
10.	Seiya Ichihara, Hirokazu Ogino, Hiroto Yoneda, Keiko Haji, Kozo Kagawa, Kojin Murakami, Masato Mima, Yu Aoi, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody., Respiratory Medicine Case Reports, Vol.41, 101797, 2022. (Summary) A man with non-small-cell lung cancer who was negative for anti-nuclear antibodies was admitted for dyspnea after immune checkpoint inhibitor (ICI) administration. Computed tomography (CT) showed complexed radiologic features, including subpleural and basal predominant reticular shadow with cystic structures and peribronchovascular consolidation. Although we treated him with high-dose steroid under a diagnosis of ICI-related pneumonitis, he developed acute exacerbation of pneumonitis with progressive fibrosis and volume loss. A re-evaluation identified anti-aminoacyl-tRNA synthetase antibody in the serum collected before ICI administration. This case highlights the importance of re-evaluating pre-existing autoimmune disorders in patients who develop ICI-related pneumonitis with atypical radiologic features. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.rmcr.2022.101797 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36583061 ● Search Scopus @ Elsevier (PMID): 36583061 ● Search Scopus @ Elsevier (DOI): 10.1016/j.rmcr.2022.101797 (DOI: 10.1016/j.rmcr.2022.101797, PubMed: 36583061)
11.	Masaki Hanibuchi, Atsushi Mitsuhashi, Tatsuya Kajimoto, Atsuro Saijo, Seidai Satou, Tetsuya Kitagawa and Yasuhiko Nishioka : Clinical significance of fractional exhaled nitric oxide and periostin as potential markers to assess therapeutic efficacy in patients with cough variant asthma., Respiratory Investigation, Vol.61, No.1, 16-22, 2022. (Summary) Our observations indicate the usefulness of FeNO and periostin as potential "therapeutic" markers for CVA. To the best of our knowledge, this is the first report demonstrating the clinical significance of these factors as potential biomarkers to assess therapeutic efficacy in patients with CVA. (Keyword) Humans / Cough / Fractional Exhaled Nitric Oxide Testing / Prospective Studies / Clinical Relevance / ROC Curve / nitric oxide / Exhalation / Asthma / Biomarkers / Breath Tests (Link to Publication Site) ● Publication site (DOI): 10.1016/j.resinv.2022.10.006 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36463016 ● Search Scopus @ Elsevier (PMID): 36463016 ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2022.10.006 (DOI: 10.1016/j.resinv.2022.10.006, PubMed: 36463016)
12.	T Na Nguyen, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Tania Afroj, Seidai Satou, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka : S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor., Cancer Science, Vol.114, No.2, 384-398, 2022. (Summary) Myeloid-derived suppressor cells (MDSCs) have been known to play a pivotal role in the induction of immune tolerance, which limits the benefits of immune checkpoint inhibitors (ICIs). Recent studies revealed that several chemotherapeutic agents decreased tumor-infiltrating MDSCs. Therefore, combination therapy with cytotoxic chemotherapeutic agents and ICIs was approved for first-line treatment for lung cancer. However, the impact of chemotherapeutic agents on MDSCs and an optimal partner of ICIs has not been fully investigated in thoracic tumors, including lung cancer and malignant pleural mesothelioma. In the present study, we found that treatment with 5-FU and its oral formulation, S-1, suppressed tumor progression and inhibited the accumulation of MDSCs in thoracic tumor-bearing mice. Tumor-infiltrating T cells and dendritic cells were significantly expanded in S-1-treated mice. 5-FU suppressed the ability of tumor cells to recruit MDSCs, while it did not suppress the survival and differentiation of mouse MDSCs in vitro. We also revealed that 5-FU or S-1 significantly downregulated the expression of tumor-derived Bv8 and S100A8. The knockdown of Bv8 or S100A8 in tumor cells suppressed tumor growth and MDSC recruitment in vivo. Furthermore, in comparison with pemetrexed, administration of S-1 improved the synergistic therapeutic efficacy of anti-PD-1 antibodies with or without carboplatin. Our findings revealed a novel mechanism wherein S-1 primed a favorable tumor microenvironment to provide the rationale for combination therapy with S-1 and ICIs as the optimal therapy for thoracic cancer. (Keyword) Mice / Animals / Myeloid-Derived Suppressor Cells / Calgranulin A / T lymphocytes / Thoracic Neoplasms / Lung Neoplasms / Tumor Microenvironment / Cell Line, Tumor (Tokushima University Institutional Repository) ● Metadata: 118295 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.15620 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36285504 ● Search Scopus @ Elsevier (PMID): 36285504 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.15620 (Tokushima University Institutional Repository: 118295, DOI: 10.1111/cas.15620, PubMed: 36285504)
13.	Kozo Kagawa, Seidai Satou, Kazuya Koyama, Takeshi Imakura, Kojin Murakami, Yuya Yamashita, Nobuhito Naito, Hirohisa Ogawa, Hiroshi Kawano and Yasuhiko Nishioka : The lymphocyte-specific protein tyrosine kinase-specific inhibitor A-770041 attenuates lung fibrosis via the suppression of TGF-β production in regulatory T-cells., PLoS ONE, Vol.17, No.10, e0275987, 2022. (Summary) These results suggest that Lck inhibition attenuated lung fibrosis by suppressing TGF-β production in Tregs and support the role of Tregs in the pathogenesis of lung fibrosis. (Keyword) Mice / Animals / pulmonary fibrosis / T-Lymphocytes, Regulatory / Transforming Growth Factor beta1 / Bleomycin / Transforming Growth Factor beta / Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / Mice, Inbred C57BL (Tokushima University Institutional Repository) ● Metadata: 118786 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0275987 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36301948 ● Search Scopus @ Elsevier (PMID): 36301948 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0275987 (Tokushima University Institutional Repository: 118786, DOI: 10.1371/journal.pone.0275987, PubMed: 36301948)
14.	Makoto Tobiume, Atsushi Mitsuhashi, Atsuro Saijo, Hirokazu Ogino, Tania Afroj, Hirohisa Ogawa, Hisatsugu Goto, Seidai Satou, Akane Abe, Keiko Haji, Ryohiko Ozaki, Hiromitsu Takizawa and Yasuhiko Nishioka : Analysis of the chemotactic factors for tumor-infiltrating fibrocytes and their prognostic significances in lung cancer., Oncology Letters, Vol.24, No.5, 417, 2022. (Summary) Fibrocytes, which are bone marrow-derived collagen-producing cells, have been reported to be involved in pathogenesis of pulmonary fibrosis. Our previous study reported that tumor-infiltrating fibrocytes play a role in tumor progression and drug resistance in lung cancer. The present study therefore examined chemotactic factors for fibrocytes in tissues of non-small cell lung cancer (NSCLC) and their prognostic significance. Surgically resected tumor tissues were examined for the expression of chemotactic factors, including C-X-C motif chemokine 12 (CXCL12), CCL2, platelet-derived growth factor (PDGF)-AA and PDGF-BB, as well as tumor-infiltrating fibrocytes by immunostaining. The chemotactic ability of fibrocytes in response to each factor was evaluated using a migration assay by counting the migrated cells microscopically, and expression of receptors for chemotactic factors were analyzed by flow cytometry. The expression of CXCL12, but not CCL2, PDGF-AA, or PDGF-BB, was associated with the number of tumor-infiltrating fibrocytes in lung adenocarcinoma (LUAD), but not lung squamous cell carcinoma (LUSQ). In addition, patients with an increased expression of CXCL12 in LUAD but not LUSQ showed a significantly poorer prognosis compared with those with a decreased expression. However, the expression of CCL2, PDGF-AA and PDGF-BB was not correlated with the prognosis of patients with NSCLC. The number of fibrocytes was associated with a poor prognosis in LUAD. Fibrocytes derived from the peripheral blood of healthy subjects as well as patients with lung cancer expressed higher levels of CXCR4 compared with CCR2, PDGF and receptor-α and receptor-β. Overall, these results suggested that targeting tumor-infiltrating fibrocytes via the CXCL12/CXCR4 axis may be a useful strategy for controlling the progression of NSCLC, particularly LUAD. (Link to Publication Site) ● Publication site (DOI): 10.3892/ol.2022.13537 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36245829 ● Search Scopus @ Elsevier (PMID): 36245829 ● Search Scopus @ Elsevier (DOI): 10.3892/ol.2022.13537 (DOI: 10.3892/ol.2022.13537, PubMed: 36245829)
15.	Takumi Sakurada, Hiroshi Nokihara, Tadashi Koga, Yoshito Zamami, Mitsuhiro Goda, Kenta Yagi, Hirofumi Hamano, Fuka Aizawa, Hirokazu Ogino, Seidai Satou, Yasushi Kirino, Hisatsugu Goto, Yasuhiko Nishioka and Keisuke Ishizawa : Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study., The Oncologist, Vol.27, No.7, e554-e560, 2022. (Summary) Prophylactic administration of low-dose dexamethasone for 5 days from the day after pemetrexed administration resulted in a milder incidence and severity of rash. These findings may provide a standard preventative strategy for pemetrexed-induced rashes. (Trial identifier: UMIN000025666). (Keyword) Adrenal Cortex Hormones / Carcinoma, Non-Small-Cell Lung / Cisplatin / Dexamethasone / Exanthema / Humans / Lung Neoplasms / Mesothelioma, Malignant / Pemetrexed (Tokushima University Institutional Repository) ● Metadata: 117391 (Link to Publication Site) ● Publication site (DOI): 10.1093/oncolo/oyab077 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35325241 ● Search Scopus @ Elsevier (PMID): 35325241 ● Search Scopus @ Elsevier (DOI): 10.1093/oncolo/oyab077 (Tokushima University Institutional Repository: 117391, DOI: 10.1093/oncolo/oyab077, PubMed: 35325241)
16.	Takeshi Imakura, Seidai Satou, Tetsu Tomonari, Kojin Murakami, Naoki Takahashi, Nobuhito Naito, Masato Mima, Kozo Kagawa, Kazuya Koyama, Haruka Nishimura, Hiroshi Kawano, Hiroshi Nokihara, Masahiko Azuma, Tetsuji Takayama and Yasuhiko Nishioka : Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma., Internal Medicine, Vol.61, No.8, 1211-1217, 2021. (Summary) Lenvatinib is a multi-targeted tyrosine kinase inhibitor available for the treatment of unresectable hepatocellular carcinoma (HCC). We herein report an 84-year-old-man with interstitial pneumonia caused by lenvatinib. Four months after the start of lenvatinib administration for HCC, chest computed tomography revealed bilateral ground-glass opacity. However, he continued to take lenvatinib for four more months until he complained of dyspnea on exertion. This is a case of lenvatinib-induced interstitial pneumonia that progressed relatively slowly with a long asymptomatic period despite the appearance of pneumonia on image findings. (Keyword) Aged, 80 and over / Carcinoma, Hepatocellular / Humans / Liver Neoplasms / Lung Diseases, Interstitial / male / Phenylurea Compounds / Quinolines (Tokushima University Institutional Repository) ● Metadata: 118011 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.7300-21 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34544944 ● Search Scopus @ Elsevier (PMID): 34544944 ● Search Scopus @ Elsevier (DOI): 10.2169/internalmedicine.7300-21 (Tokushima University Institutional Repository: 118011, DOI: 10.2169/internalmedicine.7300-21, PubMed: 34544944)
17.	Keiko Haji, Seidai Satou, Hiroto Yoneda, Toshihiko Nisisho, Hiroshi Nokihara and Yasuhiko Nishioka : Multidisciplinary treatment of skeletal muscle metastasis from lung cancer: A case of triceps muscle metastasis of lung squamous cell cancer., Respiratory Medicine Case Reports, Vol.33, 2021. (Summary) A 62-year-old Japanese man presented a hard and painful intramuscular mass in the right upper arm during the chemotherapy for lung squamous cell carcinoma. Initially, this mass containing fluid accumulation was treated by radiotherapy and antibiotics as a muscle metastasis suspected to be complicated with local infection. However, because the swelling and pain of his right arm did not improve, he underwent a surgical debridement of the mass. These local treatments succeeded in relieving the patient's symptoms for a while. However, after temporary remission, the recurrence tumor developed the paralysis of right radial nerve and ulnar nerve in his upper arm. Despite further combined therapy including drainage, additional radiotherapy, and chemotherapy, paralysis made his performance status deteriorated. He was eventually discontinued aggressive treatment due to worsened general condition. We herein report a case of lung cancer followed unusual course due to muscle metastasis in the triceps muscle. Because the paralysis caused by muscle metastasis can be the factor to deteriorate the performance status of patient, the combined therapy including antibiotics, debridement, radiotherapy and chemotherapy as early as possible should be considered to avoid its risk. (Tokushima University Institutional Repository) ● Metadata: 117385 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.rmcr.2021.101470 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34401306 ● Search Scopus @ Elsevier (PMID): 34401306 ● Search Scopus @ Elsevier (DOI): 10.1016/j.rmcr.2021.101470 (Tokushima University Institutional Repository: 117385, DOI: 10.1016/j.rmcr.2021.101470, PubMed: 34401306)
18.	Seidai Satou, Giin Sy Chong, Chandak Upagupta, Toyoshi Yanagihara, Takuya Saito, Chiko Shimbori, Pierre-Simon Bellaye, Yasuhiko Nishioka and Rj Martin Kolb : Fibrotic extracellular matrix induces release of extracellular vesicles with pro-fibrotic miRNA from fibrocytes., Thorax, Vol.76, No.9, 895-906, 2021. (Summary) Our results indicate that ECM contributes to fibrogenesis through biomechanical and biochemical effects on miRNA expression in fibrocytes. (Link to Publication Site) ● Publication site (DOI): 10.1136/thoraxjnl-2020-215962 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33859055 ● Search Scopus @ Elsevier (PMID): 33859055 ● Search Scopus @ Elsevier (DOI): 10.1136/thoraxjnl-2020-215962 (DOI: 10.1136/thoraxjnl-2020-215962, PubMed: 33859055)
19.	Hiroshi Kawano, Kazuya Koyama, Haruka Nishimura, Yuko Toyoda, Kozo Kagawa, Seidai Satou, Nobuhito Naito, Hisatsugu Goto, Yutaka Inagaki and Yasuhiko Nishioka : Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain., Immunity, Inflammation and Disease, Vol.9, No.1, 120-127, 2020. (Summary) Our findings suggest that the improved method can be a useful for the detection of pure lung fibrocytes and allows us to further analyze the characteristics of viable fibrocytes. (Tokushima University Institutional Repository) ● Metadata: 116531 (Link to Publication Site) ● Publication site (DOI): 10.1002/iid3.361 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33369271 ● Search Scopus @ Elsevier (PMID): 33369271 ● Search Scopus @ Elsevier (DOI): 10.1002/iid3.361 (Tokushima University Institutional Repository: 116531, DOI: 10.1002/iid3.361, PubMed: 33369271)
20.	Shun Morizumi, Seidai Satou, Kazuya Koyama, Hiroyasu Okazaki, Yajuan Chen, Hisatsugu Goto, Kozo Kagawa, Hirohisa Ogawa, Haruka Nishimura, Hiroshi Kawano, Yuko Toyoda, Hisanori Uehara and Yasuhiko Nishioka : Blockade of Pan-Fibroblast Growth Factor Receptors Mediates Bidirectional Effects in Lung Fibrosis., American Journal of Respiratory Cell and Molecular Biology, Vol.63, No.3, 317-326, 2020. (Summary) H]thymidine incorporation assays. The expression of FGFR was analyzed using IB or flow cytometry. We also investigated the effect of BGJ398 on pulmonary fibrosis induced by bleomycin in mice. Both lung fibroblasts and AECs expressed FGFRs. BGJ398 significantly inhibited the proliferation and migration of lung fibroblasts stimulated with FGF2. BGJ398 also reduced the proliferation of AECs in response to FGF2. Although the administration of BGJ398 ameliorated pulmonary fibrosis in bleomycin-treated mice, it increased mortality resulting from alveolar injury and inhibition of AEC regeneration. These data suggest that the total inhibition of FGFR signaling can suppress lung fibrosis by inhibiting fibroblast activities, although alveolar injury is simultaneously caused. (Keyword) Alveolar Epithelial Cells / Animals / Bleomycin / Fibroblasts / Humans / Idiopathic Pulmonary Fibrosis / Indoles / Lung / Mice / phosphorylation / Receptors, Fibroblast Growth Factor / signal transduction (Tokushima University Institutional Repository) ● Metadata: 115073 (Link to Publication Site) ● Publication site (DOI): 10.1165/rcmb.2019-0090OC (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32338990 ● Search Scopus @ Elsevier (PMID): 32338990 ● Search Scopus @ Elsevier (DOI): 10.1165/rcmb.2019-0090OC (Tokushima University Institutional Repository: 115073, DOI: 10.1165/rcmb.2019-0090OC, PubMed: 32338990)
21.	Shuichi Abe, Seidai Satou, Yoshinori Aono, Momoyo Azuma, Masami Kishi, Koyama Kazuya, Takahashi Naoki, Kozo Kagawa, Hiroshi Kawano and Yasuhiko Nishioka : Functional analysis of human fibrocytes derived from monocytes reveals their profibrotic phenotype through paracrine effects, The Journal of Medical Investigation : JMI, Vol.67, No.1.2, 102-112, 2020. (Summary) Fibrocytes, which are bone marrow-derived collagen-producing cells, were reported to play a role in the pathogenesis of pulmonary fibrosis. However, their function in pulmonary fibrosis is unclear. We analyzed their function compared with that of monocytes and localization in fibrotic tissues in patients with idiopathic pulmonary fibrosis (IPF). We compared the gene expression profile of monocyte-derived fibrocytes with that of monocytes by microarray analysis. Proliferation and differentiation into myofibroblasts were examined by 3H-thymidine incorporation assay and Western blotting. We measured the level of growth factors in the culture supernatant of fibrocytes by ELISA. The localization of fibrocytes in lung tissues of patients with IPF was determined by immunofluorescence staining. Compared with monocytes, fibrocytes had higher expression of extracellular matrix- and growth factor-encoding genes, including PDGF-B, FGF-2 and VEGF-B. Although fibrocytes did not proliferate in response to PDGF, co-culture of fibrocytes stimulated the growth of lung fibroblasts through the production of PDGF-BB. In the lung of IPF patients, CD45+Collagen-I+FSP-1+ cells, which have a similar phenotype to fibrocytes, were detected and co-stained with anti-PDGF antibody. This study suggested that fibrocytes function in pulmonary fibrosis partly by producing PDGF in the lungs of IPF patients. J. Med. Invest. 67 : 102-112, February, 2020. (Tokushima University Institutional Repository) ● Metadata: 114734 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.102 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32378592 ● Search Scopus @ Elsevier (PMID): 32378592 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.102 (Tokushima University Institutional Repository: 114734, DOI: 10.2152/jmi.67.102, PubMed: 32378592)
22.	Takeshi Imakura, Yuko Toyoda, Seidai Satou, Kazuya Koyama, Haruka Nishimura, Kozo Kagawa, Naoki Takahashi, Nobuhito Naito, Kojin Murakami, Hiroshi Kawano, Masahiko Azuma, Tsutomu Shinohara and Yasuhiko Nishioka : Distinct improvement of pulmonary function, ground-glass opacity, hypoxia and physical findings in an idiopathic pulmonary fibrosis patient after pirfenidone treatment : a case report with a review of the literature., The Journal of Medical Investigation : JMI, Vol.67, No.3.4, 358-361, 2020. (Summary) Background : Pirfenidone (PFD), an anti-fibrosis drug for idiopathic pulmonary fibrosis (IPF), suppresses disease progression and delays decline of forced vital capacity. However, this drug rarely makes marked improvement of pulmonary function, chest high-resolution computed tomography (HRCT) findings and hypoxia. Case presentation : A 59 year-old-man, who was a former smoker and had a history of alcoholic liver cirrhosis, developed exertional dyspnea and was referred to our hospital. HRCT showed honeycomb changes with surrounding ground-glass opacity (GGO) in a predominantly basal and subpleural distribution. He was diagnosed with IPF and the treatment with PFD was started. At 16 months after the start of treatment, the predicted forced vital capacity value markedly improved from 82.9% to 98.6%. His resting-state partial pressure of arterial oxygen while breathing room air increased from a minimum of 54.7 mmHg (at 2 months treatment) to 72.5 mmHg. The GGO observed at diagnosis disappeared in HRCT. But after 32 months of treatment, his general condition got worse gradually, and he died from chronic progression of IPF after 48 months of treatment. Conclusion : Our case suggests that a complication of chronic liver disease and the existence of GGO may be characteristics of super-responder to PFD treatment for IPF patients. J. Med. Invest. 67 : 358-361, August, 2020. (Tokushima University Institutional Repository) ● Metadata: 115454 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.358 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33148916 ● Search Scopus @ Elsevier (PMID): 33148916 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.67.358 (Tokushima University Institutional Repository: 115454, DOI: 10.2152/jmi.67.358, PubMed: 33148916)
23.	Hiroyasu Okazaki, Seidai Satou, Kazuya Koyama, Shun Morizumi, Shuichi Abe, Momoyo Azuma, Yajuan Chen, Hisatsugu Goto, Yoshinori Aono, Hirohisa Ogawa, Kozo Kagawa, Haruka Nishimura, Hiroshi Kawano, Yuko Toyoda, Hisanori Uehara, Hiroyuki Kouji and Yasuhiko Nishioka : The novel inhibitor PRI-724 for Wnt/β-catenin/CBP signaling ameliorates bleomycin-induced pulmonary fibrosis in mice., Experimental Lung Research, Vol.45, No.7, 188-199, 2019. (Summary) These results suggest that the β-catenin/CBP inhibitor PRI-724 is a potent antifibrotic agent that acts by modulating the activity of macrophages in the lungs. (Tokushima University Institutional Repository) ● Metadata: 113984 (Link to Publication Site) ● Publication site (DOI): 10.1080/01902148.2019.1638466 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31298961 ● Summary page in Scopus @ Elsevier: 2-s2.0-85068899202 (Tokushima University Institutional Repository: 113984, DOI: 10.1080/01902148.2019.1638466, PubMed: 31298961, Elsevier: Scopus)
24.	Yuko Toyoda, Kazuya Koyama, Hiroshi Kawano, Haruka Nishimura, Kozo Kagawa, Shun Morizumi, Nobuhito Naito, Seidai Satou, Yuya Yamashita, Naoki Takahashi, Hisatsugu Goto, Masahiko Azuma and Yasuhiko Nishioka : Clinical features of interstitial pneumonia associated with systemic lupus erythematosus., Respiratory Investigation, Vol.57, No.5, 435-443, 2019. (Summary) In SLE cases, IP primarily occurred in male and elderly patients. In addition to the NSIP pattern, the UIP pattern was evident on HRCT scans of IP-related SLE. The survival of SLE patients was unrelated to IP. (Keyword) Adult / Age of Onset / Aged / Disease Progression / Female / Humans / Incidence / Lung Diseases, Interstitial / Lupus Erythematosus, Systemic / Male / Middle Aged / Retrospective Studies / Sex Factors / Tomography, X-Ray Computed / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1016/j.resinv.2019.04.005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31235450 ● Search Scopus @ Elsevier (PMID): 31235450 ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2019.04.005 (DOI: 10.1016/j.resinv.2019.04.005, PubMed: 31235450)
25.	Masaki Hanibuchi, Akira Kanoh, Takuya Kuramoto, Tatsuro Saito, Makoto Tobiume, Atsuro Saijo, Hiroyuki Kozai, Mayo Kondou, Shun Morizumi, Hiroto Yoneda, Kozo Kagawa, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Kenji Otsuka, Yuko Toyoda, Hiroshi Nokihara, Hisatsugu Goto and Yasuhiko Nishioka : Development, validation, and comparison of gene analysis methods for detecting mutation from non-small cell lung cancer patients-derived circulating free DNA., Oncotarget, Vol.10, No.38, 3654-3666, 2019. (Tokushima University Institutional Repository) ● Metadata: 115668 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.26951 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31217900 ● Search Scopus @ Elsevier (PMID): 31217900 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.26951 (Tokushima University Institutional Repository: 115668, DOI: 10.18632/oncotarget.26951, PubMed: 31217900)
26.	Kazuya Koyama, Hisatsugu Goto, Shun Morizumi, Kozo Kagawa, Haruka Nishimura, Seidai Satou, Hiroshi Kawano, Yuko Toyoda, Hirohisa Ogawa, Sakae Homma and Yasuhiko Nishioka : The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice., American Journal of Respiratory Cell and Molecular Biology, Vol.60, No.4, 478-487, 2019. (Summary) The signaling pathways of growth factors, including platelet-derived growth factor, can be considered specific targets for overcoming the poor prognosis of idiopathic pulmonary fibrosis. Nintedanib, the recently approved multiple kinase inhibitor, has shown promising antifibrotic effects in patients with idiopathic pulmonary fibrosis; however, its efficacy is still limited, and in some cases, treatment discontinuation is necessary owing to toxicities such as gastrointestinal disorders. Therefore, more effective agents with less toxicity are still needed. TAS-115 is a novel multiple tyrosine kinase inhibitor that preferably targets platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor, and c-FMS in addition to other molecules. In this study, we evaluated the antifibrotic effect of TAS-115 on pulmonary fibrosis in vitro and in vivo. TAS-115 inhibited the phosphorylation of PDGFR on human lung fibroblast cell line MRC-5 cells and suppressed their platelet-derived growth factor-induced proliferation and migration. Furthermore, TAS-115 inhibited the phosphorylation of c-FMS, a receptor of macrophage colony-stimulating factor, in murine bone marrow-derived macrophages and decreased the production of CCL2, another key molecule for inducing pulmonary fibrosis, under the stimulation of macrophage colony-stimulating factor. Importantly, the inhibitory effects of TAS-115 on both PDGFR and c-FMS were 3- to 10-fold higher than those of nintedanib. In a mouse model of bleomycin-induced pulmonary fibrosis, TAS-115 significantly inhibited the development of pulmonary fibrosis and the collagen deposition in bleomycin-treated lungs. These data suggest that strong inhibition of PDGFR and c-FMS by TAS-115 may be a promising strategy for overcoming the intractable pathogenesis of pulmonary fibrosis. (Keyword) Animals / Bleomycin / Cell Line / Cell Movement / Cell Proliferation / Humans / Male / Mice / Mice, Inbred C57BL / Phosphorylation / Protein Kinase Inhibitors / Pulmonary Fibrosis / Quinolines / Receptor, Macrophage Colony-Stimulating Factor / Receptors, Platelet-Derived Growth Factor / Receptors, Vascular Endothelial Growth Factor / Thiourea (Link to Publication Site) ● Publication site (DOI): 10.1165/rcmb.2018-0098OC (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30540913 ● Search Scopus @ Elsevier (PMID): 30540913 ● Search Scopus @ Elsevier (DOI): 10.1165/rcmb.2018-0098OC (DOI: 10.1165/rcmb.2018-0098OC, PubMed: 30540913)
27.	Masami Kishi, Yoshinori Aono, Seidai Satou, Kazuya Koyama, Momoyo Azuma, Shuichi Abe, Hiroshi Kawano, Jun Kishi, Yuko Toyoda, Hiroyasu Okazaki, Hirohisa Ogawa, Hisanori Uehara and Yasuhiko Nishioka : Blockade of platelet-derived growth factor receptor-β, not receptor-α ameliorates bleomycin-induced pulmonary fibrosis in mice., PLoS ONE, Vol.13, No.12, 2018. (Summary) Platelet-derived growth factor (PDGF) has been implicated in the pathogenesis of pulmonary fibrosis. Nintedanib, a multi-kinase inhibitor that targets several tyrosine kinases, including PDGF receptor (PDGFR), was recently approved as an anti-fibrotic agent to reduce the deterioration of FVC in patients with idiopathic pulmonary fibrosis (IPF). However, the effects of PDGFR-α or -β on pulmonary fibrosis remain unclear. In an attempt to clarify their effects, we herein used blocking antibodies specific for PDGFR-α (APA5) and -β (APB5) in a bleomycin (BLM)-induced pulmonary fibrosis mouse model. The effects of these treatments on the growth of lung fibroblasts were examined using the 3H-thymidine incorporation assay in vitro. The anti-fibrotic effects of these antibodies were investigated with the Ashcroft score and collagen content of lungs treated with BLM. Their effects on inflammatory cells in the lungs were also analyzed using bronchoalveolar lavage fluid. We investigated damage to epithelial cells and the proliferation of fibroblasts in the lungs. APA5 and APB5 inhibited the phosphorylation of PDGFR-α and -β as well as the proliferation of lung fibroblasts induced by PDGF-AA and BB. The administration of APB5, but not APA5 effectively inhibited BLM-induced pulmonary fibrosis in mice. Apoptosis and the proliferation of epithelial cells and fibroblasts were significantly decreased by the treatment with APB5, but not by APA5. The late treatment with APB5 also ameliorated fibrosis in lungs treated with BLM. These results suggest that PDGFR-α and -β exert different effects on BLM-induced pulmonary fibrosis in mice. A specific approach using the blocking antibody for PDGFR-β may be useful for the treatment of pulmonary fibrosis. (Tokushima University Institutional Repository) ● Metadata: 113268 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0209786 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30596712 ● Search Scopus @ Elsevier (PMID): 30596712 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0209786 (Tokushima University Institutional Repository: 113268, DOI: 10.1371/journal.pone.0209786, PubMed: 30596712)
28.	Seidai Satou, Shinohara Shintaro, Hayashi Shinya, Morizumi Shun, Abe Shuichi, Okazaki Hiroyasu, Chen Yanjuan, Hisatsugu Goto, Yoshinori Aono, Hirohisa Ogawa, Koyama Kazuya, Nishimura Haruka, Hiroshi Kawano, Yuko Toyoda, Hisanori Uehara and Yasuhiko Nishioka : Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity., Respiratory Research, Vol.18, No.1, 172, 2017. (Summary) Nintedanib, a tyrosine kinase inhibitor that is specific for platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and vascular endothelial growth factor receptors (VEGFR), has recently been approved for idiopathic pulmonary fibrosis. Fibrocytes are bone marrow-derived progenitor cells that produce growth factors and contribute to fibrogenesis in the lungs. However, the effects of nintedanib on the functions of fibrocytes remain unclear. Human monocytes were isolated from the peripheral blood of healthy volunteers. The expression of growth factors and their receptors in fibrocytes was analyzed using ELISA and Western blotting. The effects of nintedanib on the ability of fibrocytes to stimulate lung fibroblasts were examined in terms of their proliferation. The direct effects of nintedanib on the differentiation and migration of fibrocytes were also assessed. We investigated whether nintedanib affected the accumulation of fibrocytes in mouse lungs treated with bleomycin. Human fibrocytes produced PDGF, FGF2, and VEGF-A. Nintedanib and specific inhibitors for each growth factor receptor significantly inhibited the proliferation of lung fibroblasts stimulated by the supernatant of fibrocytes. Nintedanib inhibited the migration and differentiation of fibrocytes induced by growth factors in vitro. The number of fibrocytes in the bleomycin-induced lung fibrosis model was reduced by the administration of nintedanib, and this was associated with anti-fibrotic effects. These results support the role of fibrocytes as producers of and responders to growth factors, and suggest that the anti-fibrotic effects of nintedanib are at least partly mediated by suppression of fibrocyte function. (Keyword) Animals / Cell Movement / Cells, Cultured / Dose-Response Relationship, Drug / Fibroblasts / Humans / Indoles / Male / Mice / Mice, Inbred C57BL / Pulmonary Fibrosis / Treatment Outcome / Vascular Endothelial Growth Factor A (Tokushima University Institutional Repository) ● Metadata: 114546 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12931-017-0654-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28915889 ● Summary page in Scopus @ Elsevier: 2-s2.0-85029541214 (Tokushima University Institutional Repository: 114546, DOI: 10.1186/s12931-017-0654-2, PubMed: 28915889, Elsevier: Scopus)
29.	Yuko Toyoda, Masaki Hanibuchi, Jun Kishi, Hiroshi Kawano, Shun Morizumi, Seidai Satou, M Kondo, Terumi Takikura, Toshifumi Tezuka, Hisatsugu Goto and Yasuhiko Nishioka : Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease., The Journal of Medical Investigation : JMI, Vol.63, No.3,4, 294-299, 2016. (Summary) Acute exacerbation (AE) of interstitial lung disease is reported to be developed in not only idiopathic pulmonary fibrosis but also connective tissue disease-associated interstitial pneumonia (CTD-IP). As the significance of AE of CTD-IP has not been so widely recognized, its clinical feature is not fully elucidated. In the present study, we investigated the incidence, clinical features and outcome of AE of CTD-IP. We retrospectively reviewed admitted cases in our department with medical record from 2011 to 2015. Among 155 patients with CTD-IP, 10 (6.5%) cases developed AE (6 rheumatoid arthritis, 2 polymyositis/dermatomyositis, 1 systemic lupus erythematosus, 1 Sjögren syndrome), and one died of AE within 30 days. Median survival time after the onset of AE was 169 days in all 10 patients. The treatment with immunosuppressant just before AE onset might improve the prognosis of AE. The median survival time after the onset of AE was significantly longer in patients showing good response to corticosteroid compared with those with poor response to corticosteroid (805 days and 45 days, respectively) (p <0.05), suggesting that there are some cases in CTD-IP, showing the good response to corticosteroid even when AE was complicated. J. Med. Invest. 63: 294-299, August, 2016. (Tokushima University Institutional Repository) ● Metadata: 111197 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.63.294 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27644575 ● Summary page in Scopus @ Elsevier: 2-s2.0-84987881651 (Tokushima University Institutional Repository: 111197, DOI: 10.2152/jmi.63.294, PubMed: 27644575, Elsevier: Scopus)
30.	Seidai Satou, Masaki Hanibuchi, Takahashi Mikiko, Fukuda Yuh, Morizumi Shun, Yuko Toyoda, Hisatsugu Goto and Yasuhiko Nishioka : A patient with idiopathic pleuroparenchymal fibroelastosis showing a sustained pulmonary function due to treatment with pirfenidone, Internal Medicine, Vol.55, No.5, 497-501, 2016. (Summary) The patient was a 68-year-old man presenting with body weight loss and exertional dyspnea. High-resolution computed tomography of the chest showed dense subpleural consolidation with traction bronchiectasis and volume loss predominantly in bilateral apical lesions and upper lobes. A histopathological analysis of a specimen of the right upper lobe showed histological patterns which were consistent with idiopathic pleuroparenchymal fibroelastotis (IPPFE). Treatment with pirfenidone was introduced with the expectation of its potential benefit. The effect of pirfenidone was satisfactory, and a decline in forced vital capacity was inhibited during treatment. This is the first case report suggesting the efficacy of pirfenidone for patients with IPPFE. (Tokushima University Institutional Repository) ● Metadata: 114388 (Link to Publication Site) ● Publication site (DOI): 10.2169/internalmedicine.55.5047 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26935370 ● Summary page in Scopus @ Elsevier: 2-s2.0-84959267460 (Tokushima University Institutional Repository: 114388, DOI: 10.2169/internalmedicine.55.5047, PubMed: 26935370, Elsevier: Scopus)
31.	梶田敬介, Seidai Satou, Yuko Toyoda, Satoshi Sakaguchi, Toshifumi Tezuka, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : A case of anaplastic lymphoma kinase-positive non-small cell lung cancer with a poor performance status successfully treated with crizotinib, Shikoku Acta Medica, Vol.71, No.5,6, 141-148, 2015. (Summary) A 27-year-old female was referred to our hospital for further examination of hoarseness, cough, and hemoptysis. Positron emission tomography-computed tomography revealed FDG accumulation in a huge mass in the left lower lobe, lymph nodes in the hilum, mediastinum and right cervical lesion left scapula and vertebral body. Further examination yielded the diagnosis of primary lung adenocarcinoma (cT2aN3M1b : Stage IV) harboring the anaplastic lymphoma kinase (ALK) fusion oncogene. Although her general condition was getting worse due to rapid increase of the pleural effusion, crizotinib promptly diminish the pleural effusion and ameliorated the patient's condition. The adverse events of crizotinib, such as nausea, vomiting and visual disturbance, were generally mild and well tolerable during treatment. These findings suggest that crizotinib is a promising candidate for ALK-positive non-small cell lung cancer patients even with poor performances. (Keyword) crizotinib / anaplastic lymphoma kinase / non-small cell lung cancer / performance status (Tokushima University Institutional Repository) ● Metadata: 109939 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050564287418456448 (Tokushima University Institutional Repository: 109939, CiNii: 1050564287418456448)
32.	Seidai Satou, Y Kawamata, A Takahashi, Y Imai, A Hanyu, A Okuma, M Takasugi, K Yamakoshi, H Sorimachi, H Kanda, Y Ishikawa, S Sone, Yasuhiko Nishioka, N Otani and E Hara : Ablation of the p16(INK4a) tumour suppressor reverses ageing phenotypes of klotho mice, Nature Communications, Vol.6, 7035, 2015. (Summary) The p16(INK4a) tumour suppressor has an established role in the implementation of cellular senescence in stem/progenitor cells, which is thought to contribute to organismal ageing. However, since p16(INK4a) knockout mice die prematurely from cancer, whether p16(INK4a) reduces longevity remains unclear. Here we show that, in mutant mice homozygous for a hypomorphic allele of the α-klotho ageing-suppressor gene (kl(kl/kl)), accelerated ageing phenotypes are rescued by p16(INK4a) ablation. Surprisingly, this is due to the restoration of α-klotho expression in kl(kl/kl) mice and does not occur when p16(INK4a) is ablated in α-klotho knockout mice (kl(-/-)), suggesting that p16(INK4a) is an upstream regulator of α-klotho expression. Indeed, p16(INK4a) represses α-klotho promoter activity by blocking the functions of E2Fs. These results, together with the observation that the expression levels of p16(INK4a) are inversely correlated with those of α-klotho throughout ageing, indicate that p16(INK4a) plays a previously unrecognized role in downregulating α-klotho expression during ageing. (Keyword) Aging / Animals / Cells, Cultured / Cyclin-Dependent Kinase Inhibitor p16 / Gene Expression Regulation / Genes, p16 / Glucuronidase / Humans / Male / Mice / Mice, Inbred C57BL / Phenotype / Promoter Regions, Genetic (Link to Publication Site) ● Publication site (DOI): 10.1038/ncomms8035 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25923845 ● Search Scopus @ Elsevier (PMID): 25923845 ● Search Scopus @ Elsevier (DOI): 10.1038/ncomms8035 (DOI: 10.1038/ncomms8035, PubMed: 25923845)
33.	Seidai Satou, Masaki Hanibuchi, Makoto Tobiume, Jun Kishi, Yuko Toyoda, Hiroshi Kawano, Mikiko Takahashi, Yuh Fukuda and Yasuhiko Nishioka : A case of IgG4-related interstitial lung disease showing usual interstitial pneumonia pattern: Unusual case for histological features with pathological proof, Case Reports in Clinical Pathology, Vol.2, No.1, 6-11, 2015. (Link to Publication Site) ● Publication site (DOI): 10.5430/crcp.v2n1p6 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.5430/crcp.v2n1p6 (DOI: 10.5430/crcp.v2n1p6)
34.	Seidai Satou, Hisatsugu Goto, 阿部秀一, 竹﨑彰夫, Hiroshi Kawano, Yoshinori Aono and Yasuhiko Nishioka : ヒトfibrocyte分化における遺伝子発現解析と分子標的治療薬による分化制御の検討, Respiratory Molecular Medicine, Vol.19, No.1, 135-139, 2015. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520854804901101056 (CiNii: 1520854804901101056)
35.	Seidai Satou, Masaki Hanibuchi, Asami Fukuya, Youhei Yabuki, Hiroki Bando, Terumi Yoshijima, Hisatsugu Goto, Hirohisa Ogawa and Yasuhiko Nishioka : Idiopathic pleuroparenchymal fibroelastosis is characterized by an elevated serum level of surfactant protein-D, but not krebs von den lungen-6, Lung, Vol.192, No.5, 711-717, 2014. (Summary) Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is a recently reported rare disease entity characterized by fibrotic thickening of the pleural and subpleural parenchyma predominantly in the upper lobes in idiopathic interstitial pneumonias (IIPs). Because the clinical features of this rare disease are not fully elucidated, we examined the clinical characteristics of IPPFE, especially for serum interstitial biomarkers, surfactant protein-D (SP-D), and Krebs von den Lungen-6 (KL-6). Four consecutive cases of IPPFE who fulfilled the diagnostic criteria were studied. All cases were more than 60 years of age, and were classified as underweight by body mass index. A severe restrictive ventilatory defect was found in all cases on admission. High-resolution computed tomography showed intense pleural thickening associated with fibrosis predominant in upper lobes. Histopathological findings were also confirmed in three out of four cases. Interestingly, the serum level of SP-D was markedly elevated in all cases, while KL-6 was within normal range in three out of four cases. As compared with major IIPs such as idiopathic pulmonary fibrosis and fibrotic nonspecific interstitial pneumonia, IPPFE significantly showed higher frequency of cases with a unique pattern of serum biomarkers, which is characterized by an elevated level of SP-D with a normal range of KL-6. In IPPFE, SP-D might tend to be elevated, while KL-6 was within a normal range. Further study is required to determine the pathogenesis and clinical significance of the elevated SP-D in IPPFE. (Keyword) Aged / Autopsy / Biological Markers / Biopsy / Fatal Outcome / Humans / Idiopathic Interstitial Pneumonias / Lung / Male / Middle Aged / Mucin-1 / Pleural Diseases / Pulmonary Surfactant-Associated Protein D / Pulmonary Ventilation / Retrospective Studies / Spirometry / Time Factors / Tomography, X-Ray Computed / Treatment Outcome / Up-Regulation (Link to Publication Site) ● Publication site (DOI): 10.1007/s00408-014-9599-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24880792 ● Summary page in Scopus @ Elsevier: 2-s2.0-84931443666 (DOI: 10.1007/s00408-014-9599-0, PubMed: 24880792, Elsevier: Scopus)
36.	Seidai Satou, Masaki Hanibuchi, Takuya Kuramoto, Nodoka Yamamori, Hisatsugu Goto, Hirohisa Ogawa, Atsushi Mitsuhashi, The Trung Van, Souji Kakiuchi, Shin-ichi Akiyama, Yasuhiko Nishioka and Saburo Sone : Macrophage stimulating protein promotes liver metastases of small cell lung cancer cells by affecting the organ microenvironment., Clinical & Experimental Metastasis, Vol.30, No.3, 333-344, 2012. (Summary) The organ microenvironment significantly affects the processes of cancer metastasis. Elucidating the molecular mechanisms of interaction between tumor cells and the organ microenvironment is crucial for the development of effective therapeutic strategies to eradicate cancer metastases. Macrophage stimulating protein (MSP), an activator of macrophages, regulates a pleiotropic array of effects, including proliferation, cellular motility, invasiveness, angiogenesis, and resistance to anoikis. However, the role of MSP in cancer metastasis is still largely unknown. In this study, the action of MSP on the production of metastases was determined in a multiple-organ metastasis model. The murine MSP gene was transfected into two human SCLC cell lines, SBC-5 and H1048, to establish transfectants secreting biologically active MSP. MSP gene transduction did not affect cell proliferation and motility in vitro. Intravenously inoculated MSP transfectants produced significantly larger numbers of liver metastases than parental cells or vector control clones, while there were no significant differences in bone or lung metastases among them. Immunohistochemical analyses of liver metastases revealed that tumor-associated microvessel density and tumor-infiltrating macrophages were significantly increased in lesions produced by MSP transfectants. MSP could stimulate the migration of murine macrophages and endothelial cells in vitro. Consequently, MSP may be one of the major determinants that affects the properties of tumor stroma and that produces a permissive microenvironment to promote cancer metastasis. (Keyword) Animals / Base Sequence / Blotting, Western / Cell Line, Tumor / Cell Proliferation / DNA Primers / Hepatocyte Growth Factor / Humans / Liver Neoplasms / Lung Neoplasms / Mice / Mice, SCID / Proto-Oncogene Proteins / Real-Time Polymerase Chain Reaction / Reverse Transcriptase Polymerase Chain Reaction / Transduction, Genetic / Tumor Microenvironment (Link to Publication Site) ● Publication site (DOI): 10.1007/s10585-012-9540-y (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23011677 ● Summary page in Scopus @ Elsevier: 2-s2.0-84875792986 (DOI: 10.1007/s10585-012-9540-y, PubMed: 23011677, Elsevier: Scopus)
37.	Seidai Satou, Tsutomu Shinohara and 岡野義夫 : 一般診療所における潜在的COPD患者の疫学調査, 日本胸部臨床 = The Japanese journal of chest diseases, Vol.68, No.11, 1074-1082, 2009. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1522825130378414720 (CiNii: 1522825130378414720)

Review, Commentary:

1.	Seidai Satou, 村上行人 and Yasuhiko Nishioka : 肺線維症におけるfibrocyteの役割, Respiratory Medicine, Vol.44, No.3, 336-341, Sep. 2023.
2.	Seidai Satou and Yasuhiko Nishioka : PF-ILDと抗線維化薬について, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.81, No.5, 764-770, May 2023.
3.	Yasuhiko Nishioka and Seidai Satou : 特発性間質性肺炎(IIPs)・肺線維症, Japan Medical Journal, Vol.5157, 42-43, Feb. 2023.
4.	Yasuhiko Nishioka, Kojin Murakami, Kazuya Koyama and Seidai Satou : 肺線維化機序, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.80, No.9, 1351-1355, Sep. 2022.
5.	Seidai Satou and Yasuhiko Nishioka : 間質性肺炎, レジデントノート, Vol.23, No.8, 77-84, Aug. 2021.
6.	Seidai Satou and Yasuhiko Nishioka : 特発性肺線維症の血清学的所見, The Journal of Practical Pharmacy, Vol.71, No.3, 26-31, Mar. 2020.
7.	Seidai Satou, Yasuhiko Nishioka and Kolb Martin : 線維化肺組織の細胞外基質が線維細胞のmiR-21発現に及ぼす影響の検討, Respiratory Molecular Medicine, Vol.24, No.1, 76-79, Mar. 2020. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1522825129960952064 (CiNii: 1522825129960952064)
8.	Yuko Toyoda, Seidai Satou, Hiroshi Kawano and Yasuhiko Nishioka : Antirheumatic drugs and lung disease, Respiratory Medicine, Vol.36, No.6, 618-626, Dec. 2019. (Keyword) rheumatoid arthritis (RA) / drug-induced pneumonia / methotrexate (MTX) / biological drug / disease modifying antirheumatic drugs (DMARDs) (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523388080905010944 (CiNii: 1523388080905010944)
9.	Seidai Satou and Yasuhiko Nishioka : ニンテダニブ新薬の最近の話題, 分子呼吸病, Vol.20, No.1, 100-102, Mar. 2016.
10.	Seidai Satou, Naoko Ohtani, Eiji Hara and Yasuhiko Nishioka : がん抑制遺伝子による細胞と個体老化の制御, がん分子標的治療, Vol.14, No.1, 76-81, Mar. 2016.
11.	Yasuhiko Nishioka, 阿部秀一, Seidai Satou and Hisatsugu Goto : Fibroocyte, Respiratory Medical Reserch, Vol.3, No.2, 60-63, Apr. 2015.

Proceeding of International Conference:

1.	Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Murakami Kojin, Yuya Yamashita, Danzan NandinErdene, Bando Hiroki, Keiko Haji, Nobuhito Naito, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka : A novel senolytic drug, ARV-825, ameliorates experimental lung fibrosis, ERS International Congress 2023, Milano, Sep. 2023.
2.	Hiroki Bando, Seidai Satou, Hirohisa Ogawa, Kazuya Koyama, Murakami Kojin, Yuya Yamashita, Danzan Nandin-Erdene, Keiko Haji, Nobuhito Naito, Hiroshi Kawano and Yasuhiko Nishioka : Anamorelin, a ghrelin receptor agonist, inhibited the allergic airway inflammation in mice, ERS International Congress 2023, Milano, Sep. 2023.
3.	Murakami Kojin, Nishimura Haruka, Hiroshi Kawano, Danzan Nandin-Erdene, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kazuya Koyama, Seidai Satou and Yasuhiko Nishioka : Analysis of the Anti-fibrotic Potential of JAK Inhibitors in a Bleomycin-induced Pulmonary Fibrosis Model, ATS 2023, Washington, DC, May 2023.
4.	Kazuya Koyama, Seidai Satou, Hiroshi Kawano, Hiroshi Kawano, Atsushi Mitsuhashi, Murakami Kojin, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Hirohisa Ogawa and Yasuhiko Nishioka : Evaluation of fibrocytes in silica-induced and bleomycin-induced pulmonary fibrosis model in mice by single cell RNA-seq analysis, APSR 2022, Seoul, Nov. 2022.
5.	Imakura Takeshi, Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Murakami Kojin, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : Computational drug repositioning and wet-lab validation approach identifies polo-like kinase inhibitors as potential therapeutics for pulmonary fibrosis, ERS International Congress 2022, Barcelona, Sep. 2022.
6.	Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka : A Novel Senolytic Agent, ARV-825, Ameliorates Bleomycin-InducedPulmonary Fibrosis in Mice, ATS 2022 International Conference, San Francisco, May 2022.
7.	Takeshi Imakura, Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : Computational Drug Repositioning Approach Identifies Polo-Like KinaseInhibitors as Potential Therapeutics for Pulmonary Fibrosis, ATS 2022 International Conference, San Francisco, May 2022.
8.	Kazuya Koyama, Hiroshi Kawano, Atsushi Mitsuhashi, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Seidai Satou, Hirohisa Ogawa and Yasuhiko Nishioka : Single Cell RNA-seq Analysis of Fibrocytes in Silica Induced Mouse Pulmonary Fibrosis Model, ATS 2022 International Conference, San Francisco, May 2022.
9.	Imakura Takeshi, Seidai Satou, Kazuya Koyama, Takahiro Niimura, Kohjin Murakami, Yuya Yamashita, Takahashi Naoki, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : Polo-like kinase inhibitors identified by computational repositioning attenuates bleomycin-induced pulmonary fibrosis in mice, APSR 2021, Kyoto and online, Nov. 2021.
10.	Kohjin Murakami, Takahashi Naoki, Seidai Satou, Imakura Takeshi, Yuya Yamashita, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Tanigawara Kazuaki, Toriumi Wataru and Yasuhiko Nishioka : Therapeutic effect of oligonucleotide therapeutics PK-7010 in mouse model of bleomycin-induced lung fibrosis, APSR 2021, Kyoto and online, Nov. 2021.
11.	Nobuhito Naito, Hiroshi Kawano, Imakura Takeshi, Yuya Yamashita, Kohjin Murakami, Kozo Kagawa, Kazuya Koyama, Seidai Satou, Hiroshi Nokihara, Inagaki Yutaka and Yasuhiko Nishioka : Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain, APSR 2021, Kyoto and online, Nov. 2021.
12.	Kozo Kagawa, Kazuya Koyama, Seidai Satou, Imakura Takeshi, Kohjin Murakami, Yuya Yamashita, Takahashi Naoki, Nobuhito Naito, Hiroshi Kawano and Yasuhiko Nishioka : A Lck-specific inhibitor, A-770041, attenuates pulmonary fibrosis via the suppression of TGF-b production in regulatory T cells, APSR 2021, Kyoto and online, Nov. 2021. (Link to Publication Site) ● Publication site (DOI): 10.1111/resp.14150_945 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1111/resp.14150_945 (DOI: 10.1111/resp.14150_945)
13.	Hiroshi Kawano, Nishimura Haruka, Imakura Takeshi, Yuya Yamashita, Kohjin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : Analysis of anti-fibrotic potential of JAK inhibitors in bleomycin-induced pulmonary fibrosis model, APSR 2021, Kyoto and online, Nov. 2021. (Link to Publication Site) ● Publication site (DOI): 10.1111/resp.14150_915 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1111/resp.14150_915 (DOI: 10.1111/resp.14150_915)
14.	Kozo Kagawa, Kazuya Koyama, Seidai Satou, Imakura Takeshi, Kohjin Murakami, Takahashi Naoki, Nobuhito Naito, Nishimura Haruka, Hiroshi Kawano and Yasuhiko Nishioka : Anti-fibrotic efficacy of Lck inhibitor via the suppression of TGF-β production in regulatory T cells, ERS International Congress 2021, WEB, Sep. 2021. (Link to Publication Site) ● Publication site (DOI): 10.1183/13993003.congress-2021.PA3285 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2021.PA3285 (DOI: 10.1183/13993003.congress-2021.PA3285)
15.	Takahashi Naoki, Seidai Satou, Imakura Takeshi, Kohjin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Tanigawara Kazuaki, Toriumi Wataru and Yasuhiko Nishioka : Oligonucleotide therapeutics PK-7010 in combination with nintedanib ameliorates bleomycin-induced pulmonary fibrosis in mice, ATS 2021, 米国(WEB), May 2021. (Link to Publication Site) ● Publication site (DOI): 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A4444 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A4444 (DOI: 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A4444)
16.	Kazuya Koyama, Hiroshi Kawano, Yuya Yamashita, Imakura Takeshi, Takahashi Naoki, Nobuhito Naito, Seidai Satou and Yasuhiko Nishioka : Clinical Features of the Acute Exacerbation of Rheumatoid Arthritis-Associated Interstitial Lung Disease, ATS 2021, 米国(WEB), May 2021.
17.	Takahashi Naoki, Seidai Satou, Imakura Takeshi, Murakami Kojin, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Tanigawara Kazuaki, Toriumi Wataru and Yasuhiko Nishioka : The novel oligonucleotide therapeutics PK-7010 for TGF-β1 ameliorates bleomycin-induced pulmonary fibrosis in micen, ERS International Congress 2020 Virtual, WEB, Sep. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1183/13993003.congress-2020.3373 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2020.3373 (DOI: 10.1183/13993003.congress-2020.3373)
18.	Seidai Satou, Yamamoto Takushi, Waki Kana, Morimoto Yuki, Imakura Takeshi, Murakami Kojin, Takahashi Naoki, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Koichi Tsuneyama and Yasuhiko Nishioka : Analysis of localization of nintedanib and cyclophosphamide in pulmonary fibrosisusing the iMScope TRIOS, ERS International Congress 2020 Virtual, WEB, Sep. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1183/13993003.congress-2020.3385 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2020.3385 (DOI: 10.1183/13993003.congress-2020.3385)
19.	Kazuya Koyama, Sakamoto Susumu, Homma Sakae, Seidai Satou, Masaki Hanibuchi, Masuda Kiyoshi, Imoto Isei, Yuko Toyoda, Isshiki Takuma, Miyoshi Shion, Kato Motoyasu, Takahashi Kazuhisa, Kataoka Kensuke, Kondoh Yasuhiro and Yasuhiko Nishioka : The Relationship Between Single-Nucleotide Polymorphisms Within Tollip and the Efficacy of Inhaled N-Acetylcysteine Therapy in Idiopathic Pulmonary Fibrosis, ATS 2020 VIRTUAL, WEB, Aug. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1494 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1494 (DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1494)
20.	Kozo Kagawa, Koyama Kazuya, Seidai Satou, Takahashi Naoki, Nishimura Haruka, Nobuhito Naito, Hiroshi Kawano, Yuko Toyoda and Yasuhiko Nishioka : Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice., ERS International Congress 2019, Madrid, Oct. 2019. (Link to Publication Site) ● Publication site (DOI): 10.1183/13993003.congress-2019.PA5372 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2019.PA5372 (DOI: 10.1183/13993003.congress-2019.PA5372)
21.	Koyama Kazuya, Sakamoto Susumu, Homma Sakae, Seidai Satou, Masaki Hanibuchi, Masuda Kiyoshi, Issei Imoto, Yuko Toyoda, Isshiki Takuma, Miyoshi Shion, Kato Motoyasu, Takahashi Kazuhisa, Kataoka Kensuke, Kondoh Yasuhiro and Yasuhiko Nishioka : Single-nucleotide polymorphisms within TOLLIP and the efficacy of inhaled N-acetylcysteine therapy in idiopathic pulmonary fibrosis., ERS International Congress 2019, Madrid, Sep. 2019. (Link to Publication Site) ● Publication site (DOI): 10.1183/13993003.congress-2019.PA2243 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2019.PA2243 (DOI: 10.1183/13993003.congress-2019.PA2243)
22.	Seidai Satou, Upagupta Chandak, Yanagihara Toyoshi, Kolb RJ Martin and Yasuhiko Nishioka : Expression of pro-fibrotic microRNA of fibrocytes in bronchoalveolar lavage fluid., ATS 2019 International Conference, Dallas, May 2019. (Link to Publication Site) ● Publication site (DOI): 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A5273 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A5273 (DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A5273)
23.	Hiroshi Kawano, Koyama Kazuya, Nishimura Haruka, Yuko Toyoda, Kagawa Kozo, Seidai Satou, Naito Nobuhito, Hisatsugu Goto, Inagaki Yutaka and Yasuhiko Nishioka : Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain, ERS International Congress, Paris, Sep. 2018.
24.	Yuko Toyoda, Morizumi Shun, Seidai Satou, Okazaki Hiroyasu, Chen Yanjuan, Hisatsugu Goto, Hirohisa Ogawa, Nishimura Haruka, Koyama Kazuya, Hiroshi Kawano, Yoshinori Aono, Hisanori Uehara and Yasuhiko Nishioka : Role of Fibroblast Growth Factor/Fibroblast Growth Factor Receptor Signal in Bleomycin-Induced Pulmonary Fibrosis in Mice., ATS 2017 International Conference, Washington, D.C., May 2017.
25.	Seidai Satou, Hisatsugu Goto, Shun Morizumi, Hiroyasu Okazaki, Yajuan Chen, Hiroshi Kawano, Yuko Toyoda, Masaki Hanibuchi, Masahiko Azuma and Yasuhiko Nishioka : Effect of blockade of fibroblast growth factor receptor signaling in experimental pulmonary fibrosis in mice, ATS 2016 International Conference, May 2016.
26.	Seidai Satou, Hisatsugu Goto, Abe Shuichi, Yoshijima Terumi, Okazaki Hiroyasu, Takezaki Akio, Yoshinori Aono, Masaki Hanibuchi and Yasuhiko Nishioka : Effect of kinase inhibitors for growth factor receptors on the differentiation of human fibrocytes, ATS 2015 International Conference, Denver, May 2015.
27.	Yasuhiko Nishioka, Shuichi Abe, Seidai Satou, Yoshinori Aono, Hisatsugu Goto, Masami Kishi, Terumi Yoshijima, Hiroyasu Okazaki and Masaki Hanibuchi : Role of human fibrocytes in regulating pulmonary fibrosis: comprehensive analysis of their gene expression profile and growth factor production, The 18th International Colloquium on Lung and Airway Fibrosis, Mont-Tremblant, Quebec Canada, Sep. 2014.
28.	Seidai Satou, Hisatsugu Goto, Shuichi Abe, Masami Kishi, Katsuhiro Kinoshita, Momoyo Azuma, Akio Takezaki, Jun Kishi, Yoshinori Aono, Masaki Hanibuchi and Yasuhiko Nishioka : Effect of Nintedanib (BIBF1120) on fibrocyte-induced fibroblast activation, ATS 2014 International Conference, San Diego, May 2014.

Proceeding of Domestic Conference:

1.	Noriko Bando, Hiroki Bandoh, Keiko Haji, 美馬正人, Asami Fukuya, Nobuhito Naito, Ryohiko Ozaki, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Satoshi Sakaguchi, Masaki Hanibuchi and Yasuhiko Nishioka : 当科における重症喘息に対する生物学的製剤の治療効果の検討, 第268回徳島医学会学術集会, Mar. 2024.
2.	Ryoko Suzue, Hiroki Bandoh, Keiko Haji, Ryohiko Ozaki, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 抗横紋筋抗体陽性の重症irAE筋炎・心筋炎に対して早期の集学的治療が奏効した肺扁平上皮癌の1例, 第69回日本呼吸器学会中国・四国地方会, Dec. 2023.
3.	寺澤翠, Hiroki Bandoh, Keiko Haji, Hiroto Yoneda, Hirokazu Ogino, 岡田直子, Takashi Kawanaka, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : ペプチド受容体放射性核種療法が奏効した左下葉原発進行期非定型カルチノイドの1例, 第69回日本呼吸器学会中国・四国地方会, Dec. 2023.
4.	Yu Aoi, Hiroki Bandoh, Keiko Haji, 高橋啓輝, Hiroto Yoneda, Akane Abe, Seidai Satou, Momoyo Azuma, Masaki Hanibuchi and Yasuhiko Nishioka : 気管支鏡検査で診断したCOVID-19関連肺アスペルギルス症の1例, 第32回日本呼吸器内視鏡学会中国四国支部会, Dec. 2023.
5.	中西渓介, Hiroki Bandoh, Keiko Haji, 小倉祐一郎, 美馬正人, Nobuhito Naito, Akane Abe, 川真田純, 杉浦宏, Seidai Satou, Momoyo Azuma, Masaki Hanibuchi, Koichi Sairyo and Yasuhiko Nishioka : 結核性脊椎炎の治療中にparadoxical responseとして皮下膿瘍が出現した1例, 第74 回日本結核・非結核性抗酸菌症学会中国四国支部会, Dec. 2023.
6.	Kenya Miyamoto, Masaki Hanibuchi, 坂東弘基, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 気管支鏡後の呼吸器感染症のリスク因子および予防的抗菌薬投与の有用性についての検討, 第32回日本呼吸器内視鏡学会中国四国支部会, Dec. 2023.
7.	Yuta Isomura, Hiroki Bandoh, Keiko Haji, Nobuhito Naito, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 悪性リンパ腫の治療経過中に発症したβ-Dグルカン陰性ニューモシスチス肺炎の1例, 第129回日本内科学会四国地方会, Dec. 2023.
8.	山本浩生, Hiroki Bandoh, Keiko Haji, Yuya Yamashita, Nobuhito Naito, Seidai Satou, Hiroshi Kawano, Masaki Hanibuchi and Yasuhiko Nishioka : ステロイド抵抗性の気道病変に対してシクロホスファミドが著効した再発性多発軟骨炎の1例, 第129回日本内科学会四国地方会, Dec. 2023.
9.	Hiroshi Kawano, Yu Aoi, Katsuhiro Atagi, Kojin Murakami, Yuya Yamashita, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 顕微鏡的多発血管炎の診断時にEBVの再活性化を呈し，リツキシマブにて寛解導入療法を行った1例, 第34回日本リウマチ学会中国・四国支部学術集会, Dec. 2023.
10.	Yu Aoi, Hiroshi Kawano, Katsuhiro Atagi, Kojin Murakami, Yuya Yamashita, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 胸膜炎，間質性肺疾患を先行し，発熱性好中球減少症と肺病変の増悪で発症したSLEの1例, 第34回日本リウマチ学会中国・四国支部学術集会, Dec. 2023.
11.	Seidai Satou, Masaki Hanibuchi, Atsushi Mitsuhashi and Yasuhiko Nishioka : 咳喘息治療における効果予測バイオマーカーの探索, 第72回日本アレルギー学会学術大会, Oct. 2023.
12.	Hiroki Bandoh, Seidai Satou, Kojin Murakami, Yuya Yamashita, Nobuhito Naitoh, Kazuya Koyama, Hiroshi Kawano, Hirohisa Ogawa and Yasuhiko Nishioka : グレリン受容体作動薬アナモレリンのアレルギー性気道炎症モデルマウスにおける検討, 第72回日本アレルギー学会学術大会, Oct. 2023.
13.	Hirohisa Ogawa, Mayuko Shimizu, 平修, Hiroki Bandoh, Seidai Satou, Koichi Tsuneyama and Yasuhiko Nishioka : メタボローム解析による複数抗原感作喘息モデルにおける難治性因子の探索, 第72回日本アレルギー学会学術大会, Oct. 2023.
14.	Seidai Satou, Hirohisa Ogawa, Kojin Murakami, Yuya Yamashita, Keiko Haji, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka : BRD4 阻害剤 ARV825 の線維化関連遺伝子の発現抑制と老化細胞除去を介した抗線維化効果の検討, 第3回日本びまん性肺疾患研究会, Sep. 2023.
15.	Keiko Haji, Seidai Satou, Hirohisa Ogawa, Kojin Murakami, Yuya Yamashita, Kazuya Koyama, Hiroshi Kawano, 小林克利, 諸星俊郎 and Yasuhiko Nishioka : オートタキシン阻害作用を有する 2ccPA の肺線維症における有効性の検討, 第3回日本びまん性肺疾患研究会, Sep. 2023.
16.	原田紗希, Hiroki Bandoh, Keiko Haji, Nobuhito Naito, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 当院において外科治療を施行した肺Mycobacterium avium complexの検討, 第267回徳島医学会学術集会, Aug. 2023.
17.	寺澤翠, Hiroki Bandoh, Keiko Haji, 小路貴俊, Hiroto Yoneda, Seidai Satou, Hiroshi Kawano, Masaki Hanibuchi and Yasuhiko Nishioka : シクロスポリンが有効であった血清IL-18高値の重症成人発症スティル病の1例, 第128回日本内科学会四国地方会, Jul. 2023.
18.	中西渓介, 坂東弘基, Keiko Haji, 松村有悟, 稲葉香織, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : Carboplatin+etoposideや放射線治療に不応もnab-paclitaxelが奏効した肺原発大細胞神経内分泌癌の1例, 第128回日本内科学会四国地方会, Jul. 2023.
19.	山本浩生, Hiroki Bandoh, Keiko Haji, Michihiro Kunishige, 梶本達也, Kazuya Koyama, Kozo Kagawa, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 自然経過で嚢胞性画像変化および呼吸機能の改善を認めた重症COVID-19の1例, 第68回日本呼吸器学会中国・四国地方会, Jul. 2023.
20.	多田里穂, Hiroki Bandoh, Keiko Haji, 新居香織, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 抗PD-L1抗体投与により腫瘍随伴性小脳変性症が顕在化した小細胞肺癌の1例, 第61回日本肺癌学会中国・四国支部学術集会, Jul. 2023.
21.	遠藤裕美, Hiroki Bandoh, Keiko Haji, 高橋啓輝, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 包括的ゲノムプロファイリングにより診断し得たEGFR Exon19欠失変異陽性肺腺癌の1例, 第61回日本肺癌学会中国・四国支部学術集会, Jul. 2023.
22.	Hiroki Bandoh, Seidai Satou, Kojin Murakami, Yuya Yamashita, Nobuhito Naito, Kazuya Koyama, Hiroshi Kawano, Hirohisa Ogawa and Yasuhiko Nishioka : グレリン受容体作動薬アナモレリンのアレルギー性気道炎症モデルマウスにおける検討, 第63回日本呼吸器学会学術講演会, Apr. 2023.
23.	Seidai Satou, Masaki Hanibuchi, Atsushi Mitsuhashi and Yasuhiko Nishioka : 咳喘息における呼気中一酸化窒素と血清ペリオスチンの臨床的意義の検討, 第63回日本呼吸器学会学術講演会, Apr. 2023.
24.	Masaki Hanibuchi, Atsushi Mitsuhashi, Atsuro Saijo, Seidai Satou and Yasuhiko Nishioka : スクリーニング質問票を用いたCOPD検診システムの有用性の検討, 第63回日本呼吸器学会学術講演会, Apr. 2023.
25.	Kojin Murakami, Seidai Satou, Yuya Yamashita, Keiko Haji, 坂東弘基, Nobuhito Naito, Kazuya Koyama, Hiroshi Kawano, 稲村典昭, 蓮見惠司 and Yasuhiko Nishioka : 新規可溶性エポキシヒドロラーゼ阻害薬SMTP-44Dの肺線維症に対する有効性の検討, 第63回日本呼吸器学会学術講演会, Apr. 2023.
26.	Takeshi Imakura, Seidai Satou and Yasuhiko Nishioka : ERS2022に参加して, 第63回日本呼吸器学会学術講演会, Apr. 2023.
27.	Hiroshi Kawano, 小路貴俊, Katsuhiro Atagi, Kojin Murakami, Yuya Yamashita, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : リンパ球特異的チロシンキナーゼ阻害薬A-770041は制御性T細胞によるTGF-βs産生抑制を介して肺線維症を改善する, 第67回日本リウマチ学会総会・学術集会, Apr. 2023.
28.	Seidai Satou, 山本卓志 and Yasuhiko Nishioka : イメージング質量顕微鏡iMScope TRIOによる抗線維化薬の線維性肺組織内局在分布の検討, 第14回呼吸機能イメージング研究会学術集会, Jan. 2023.
29.	松村有悟, Keiko Haji, 鈴江涼子, Hiroto Yoneda, Kozo Kagawa, Hirokazu Ogino, Seidai Satou, Hirohisa Ogawa, Masaki Hanibuchi and Yasuhiko Nishioka : 血清Krebs von den Lungen-6 が高値を示した悪性胸膜中皮腫の1例, 第127回日本内科学会四国地方会, Dec. 2022.
30.	新居香織, Keiko Haji, Yu Aoi, Yuya Yamashita, Nobuhito Naito, Hirokazu Ogino, Hiroshi Kawano, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 関節炎を呈したACTH 単独欠損症の1例, 第127回日本内科学会四国地方会, Dec. 2022.
31.	Kenya Miyamoto, Keiko Haji, 原田紗希, 鈴江涼子, Akane Abe, Momoyo Azuma, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 当院における肺MAC症に対するアジスロマイシン併用療法の有効性・安全性の検討, 第73回日本結核・非結核性抗酸菌症学会中国四国支部会, Dec. 2022.
32.	森彩花, Keiko Haji, Yu Aoi, Kenya Miyamoto, Kojin Murakami, Yuki Tsukazaki, Hiroki Bandoh, Ryohiko Ozaki, Kozo Kagawa, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 免疫チェックポイント阻害薬使用後に肺胞出血をきたした1例, 第31回日本呼吸器内視鏡学会中国四国支部会, Dec. 2022.
33.	寺澤翠, Keiko Haji, 市原聖也, Yuya Yamashita, Asami Fukuya, Nobuhito Naito, Hiroto Yoneda, Kozo Kagawa, Hirokazu Ogino, Hiroshi Kawano, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 抗PD-L1抗体投与後に顕在化した抗ARS抗体陽性間質性肺炎の1例, 第67回日本呼吸器学会中国・四国地方会, Dec. 2022.
34.	中西颯斗, Keiko Haji, 松村有悟, Atsushi Mitsuhashi, 小川瑛, Takeshi Imakura, 美馬正人, Ryohiko Ozaki, Hiroto Yoneda, Hirokazu Ogino, Satoshi Sakaguchi, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 同時に異なる3つの組織型を認めた多発性肺癌の1例, 第67回日本呼吸器学会中国・四国地方会, Dec. 2022.
35.	小路貴俊, Nobuhito Naito, Hiroshi Kawano, Kojin Murakami, Yuya Yamashita, 美馬正人, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 両側声帯麻痺を呈した多発血管炎性肉芽腫症に伴う肥厚性硬膜炎の1例, 第33回日本リウマチ学会中国・四国支部学術集会, Dec. 2022.
36.	Katsuhiro Atagi, Hiroshi Kawano, 小路貴俊, Kojin Murakami, Yuya Yamashita, 美馬正人, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 劇症1型糖尿病と同時期に発症した両側特発性外眼筋炎の1例, 第33回日本リウマチ学会中国・四国支部学術集会, Dec. 2022.
37.	Nobuhito Naito, 西村春佳, Yuya Yamashita, Kojin Murakami, Keiko Haji, Kazuya Koyama, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Masaki Hanibuchi and Yasuhiko Nishioka : ブレオマイシン誘発肺線維症モデルマウスを用いたJAK阻害薬の抗線維化効果についての検討, 第50回日本臨床免疫学会総会, Oct. 2022.
38.	Hirohisa Ogawa, Mayuko Shimizu, Seidai Satou, Koichi Tsuneyama and Yasuhiko Nishioka : リゾホスファチジン酸(LPA)はLPA1受容体を介して粘液細胞過形成を促進する, 第71回日本アレルギー学会学術大会, Oct. 2022.
39.	中西颯斗, Keiko Haji, Yohhei Yabuki, 新居香織, 高丸利加子, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : セルペルカチニブが奏功したRET融合遺伝子陽性肺腺癌の1例, 第265回徳島医学会学術集会, Jul. 2022.
40.	小倉佑一朗, Keiko Haji, 近藤健介, Kenji Otsuka, Hirokazu Ogino, Kazuya Koyama, 村上行人, Hiroki Bandoh, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 間質性肺炎への治療反応性から肝肺症候群の併存が顕在化した一例, 第66回日本呼吸器学会中国・四国地方会, Jul. 2022.
41.	松村有悟, Keiko Haji, 美馬正人, Yohhei Yabuki, Kenji Otsuka, Hiroto Yoneda, Hiroshi Nokihara, Hirokazu Ogino, Ryohiko Ozaki, 塚崎佑貴, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : 小細胞肺癌への形質転換を認めたEGFR遺伝子変異陽性肺腺癌の3例, 第60回日本肺癌学会中国・四国支部学術集会, Jul. 2022.
42.	新居香織, Yohhei Yabuki, Keiko Haji, 高丸利加子, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : セルペルカチニブが奏効したRET融合遺伝子陽性肺腺癌の1例, 第60回日本肺癌学会中国・四国支部学術集会, Jul. 2022.
43.	Keiko Haji, Yohhei Yabuki, 美馬正人, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : MET阻害薬が著効したMET遺伝子 exon14 skipping 変異陽性肺扁平上皮癌の1例, 第126回日本内科学会四国地方会, Jun. 2022.
44.	高橋啓輝, Yohhei Yabuki, 市原聖也, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 重度の嚥下障害を合併した抗Ro52抗体陽性皮膚筋炎の1例, 第126回日本内科学会四国地方会, Jun. 2022.
45.	Kojin Murakami, 原田紗希, Takeshi Imakura, Atsushi Mitsuhashi, 小川瑛, TSUKAZAKI Yuki, Ryohiko Ozaki, YABUKI Yohhei, Kozo Kagawa, Hiroto Yoneda, Akane Abe, Hirokazu Ogino, Kazuya Koyama, Seidai Satou, Satoshi Sakaguchi and Yasuhiko Nishioka : 抗GM-CSF抗体測定が早期診断に有用であった自己免疫性肺胞蛋白症の一例, 第45回日本呼吸器内視鏡学会学術集会, May 2022.
46.	Takeshi Imakura, Seidai Satou, 原田紗希, Atsushi Mitsuhashi, 小川瑛, Kojin Murakami, Yuki Tsukazaki, Ryohiko Ozaki, Yohhei Yabuki, Kozo Kagawa, Hiroto Yoneda, Akane Abe, Hirokazu Ogino, Satoshi Sakaguchi and Yasuhiko Nishioka : 肺門部・縦隔リンパ節腫大に対してEBUS-TBNAを実施し子宮頸癌再発と診断した1例, 第45回日本呼吸器内視鏡学会学術集会, May 2022.
47.	Hiroshi Kawano, Takeshi Imakura, Yuya Yamashita, Kojin Murakami, Nobuhito Naito, Seidai Satou and Yasuhiko Nishioka : ブレオマイシン誘発肺線維症モデルマウスにおけるJAK阻害薬の抗線維化効果に関する検討, 第66回日本リウマチ学会総会・学術集会, Apr. 2022.
48.	Seidai Satou, Kazuya Koyama, Hirohisa Ogawa, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Hiroshi Kawano, Eiji Hara and Yasuhiko Nishioka : Antifibrotic and senolytic activity of novel BRD4 degrader ARV825 in experimental model of lung fibrosis, The 62nd Annual Meeting of the Japanese Respiratory Society, Apr. 2022.
49.	美馬正人, Seidai Satou, 原田紗希, 鈴江涼子, Yuya Yamashita, Ryohiko Ozaki, Keiko Haji, Nobuhito Naito, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 抗ARS抗体陽性間質性肺疾患の胸部画像所見の検討, 第62回日本呼吸器学会学術講演会, Apr. 2022.
50.	Kazuya Koyama, Atsushi Mitsuhashi, Takeshi Imakura, Kojin Murakami, Kozo Kagawa, Seidai Satou, Hiroshi Kawano, Hirohisa Ogawa and Yasuhiko Nishioka : シングルセル解析を用いた肺線維症マウスモデルにおけるfibrocyteの検討, 第62回日本呼吸器学会学術講演会, Apr. 2022.
51.	Hiroshi Kawano, Takeshi Imakura, Kojin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : レポーターマウスを用いた肺線維細胞の新規同定法, 第62回日本呼吸器学会学術講演会, Apr. 2022.
52.	Takeshi Imakura, Seidai Satou, Kazuya Koyama, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : In silico解析により同定されたPLK阻害剤のブレオマイシン誘発肺線維症モデルマウスにおける効果の検討, 第62回日本呼吸器学会学術講演会, Apr. 2022.
53.	石田卓也, Hiroshi Kawano, Takeshi Imakura, Kohjin Murakami, Yuya Yamashita, 美馬正人, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 当院における膠原病関連間質性肺疾患に対するニンテダニブの使用経験, 第32回日本リウマチ学会中国・四国支部学術集会, Dec. 2021.
54.	市原聖也, Hiroshi Kawano, Takeshi Imakura, Kohjin Murakami, Yuya Yamashita, 美馬正人, Nobuhito Naito, Hirokazu Ogino, Seidai Satou and Yasuhiko Nishioka : 再発性多発軟骨炎治療中の不明熱精査でUBA1遺伝子解析により診断したVEXAS症候群の1例, 第32回日本リウマチ学会中国・四国支部学術集会, Dec. 2021.
55.	市原聖也, YABUKI Yohhei, Kohjin Murakami, Kozo Kagawa, Hiroto Yoneda, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 亜急性に進行し，蜂巣肺様の所見を呈した薬剤性肺障害の1例, 第125回日本内科学会四国地方会, Dec. 2021.
56.	石田卓也, YABUKI Yohhei, Kozo Kagawa, Yuya Yamashita, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 成人Still病との鑑別を要した家族性地中海熱非典型例の1例, 第125回日本内科学会四国地方会, Dec. 2021.
57.	村上尚哉, YABUKI Yohhei, Ryohiko Ozaki, Kozo Kagawa, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : Sitafloxacinが奏効した肺Mycobacterium abscessus subsp. massiliense 症の1例, 第72回日本結核・非結核性抗酸菌症学会中国四国支部会, Dec. 2021.
58.	高丸利加子, YABUKI Yohhei, 磯村祐太, Kozo Kagawa, Kazuya Koyama, Kenji Otsuka, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 自然退縮を認めた気管支原発唾液腺型腫瘍の1例, 第30回日本呼吸器内視鏡学会中国四国支部会, Dec. 2021.
59.	小川瑛, YABUKI Yohhei, 青井優, Kozo Kagawa, Kazuya Koyama, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 両側肺に多発する斑状影を呈した自己免疫性肺胞蛋白症の1例, 第65回日本呼吸器学会中国・四国地方会, Dec. 2021.
60.	原田祥子, YABUKI Yohhei, 美馬正人, Ryohiko Ozaki, Kozo Kagawa, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 非結核性抗酸菌症との鑑別を要し，amikacin + minocyclineが奏効した肺ノカルジア, 第65回日本呼吸器学会中国・四国地方会, Dec. 2021.
61.	Takeshi Imakura, Seidai Satou, Kazuya Koyama, Takahiro Niimura, Kohjin Murakami, Naoki Takahashi, Kozo Kagawa, Yoshito Zamami, Keisuke Ishizawa and Yasuhiko Nishioka : In silico 解析を用いた肺線維症に対する新規治療薬の探索, 第1回日本びまん性肺疾患研究会, Oct. 2021.
62.	Kohjin Murakami, Naoki Takahashi, Seidai Satou, Takeshi Imakura, Yuya Yamashita, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, 谷川原万顕, 鳥海亙 and Yasuhiko Nishioka : ブレオマイシン誘発肺線維症モデルマウスにおける新規核酸医薬の有効性の検討, 第1回日本びまん性肺疾患研究会, Oct. 2021.
63.	Seidai Satou, Yasuhiko Nishioka and Kolb Martin : 線維化肺組織の細胞外基質が線維細胞の線維化促進性miRNA 発現に及ぼす影響の検討, 第1回日本びまん性肺疾患研究会, Oct. 2021.
64.	花房翠, YABUKI Yohhei, Takeshi Imakura, Hiroto Yoneda, Akane Abe, 美馬正人, Yuya Yamashita, Nobuhito Naito, Kozo Kagawa, Kenji Otsuka, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : ステロイドパルス療法後に増悪し二度目のパルス療法が奏効したCOVID-19肺炎の1例, 第63回日本呼吸器学会中国・四国地方会, Aug. 2021.
65.	Satoshi Sakaguchi, YABUKI Yohhei, Takeshi Imakura, Hiroto Yoneda, Kohjin Murakami, Kazuya Koyama, Kozo Kagawa, 小川瑛, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 索状の小葉間隔壁の肥厚を認め胸腔鏡下肺生検にて診断した間質性肺炎の1例, 第63回日本呼吸器学会中国・四国地方会, Aug. 2021.
66.	中内友合江, YABUKI Yohhei, Keiko Haji, Hiroto Yoneda, Atsushi Mitsuhashi, 青井優, 石田卓也, 村上尚哉, Hirokazu Ogino, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : Tepotinibが著効したMET遺伝子exon14 skipping変異陽性肺腺癌の1例, 第59回日本肺癌学会中国・四国支部学術集会, Aug. 2021.
67.	市原聖也, YABUKI Yohhei, Ryohiko Ozaki, 近藤健介, Hiroto Yoneda, Kenji Otsuka, Asami Fukuya, 高丸利加子, 原田祥子, Hirokazu Ogino, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : AtezolizumabのImmune-Related Adverse Eventによる急性腎障害を認めた非小細胞肺癌の1例, 第59回日本肺癌学会中国・四国支部学術集会, Aug. 2021.
68.	高丸利加子, Nobuhito Naito, 原田紗希, YAMASHITA Yuya, Ryohiko Ozaki, Naoki Takahashi, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 当科における全身性エリテマトーデスに対するベリムマブの使用経験, 第124回日本内科学会四国地方会, May 2021.
69.	石田卓也, Nobuhito Naito, Takeshi Imakura, Kozo Kagawa, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara, Tetsuji Takayama and Yasuhiko Nishioka : レンバチニブによる薬剤性肺障害の1例, 第124回日本内科学会四国地方会, May 2021.
70.	Yuya Yamashita, Takeshi Imakura, Naoki Takahashi, Nobuhito Naito, Seidai Satou, Hiroshi Kawano and Yasuhiko Nishioka : 関節リウマチに伴う間質性肺炎急性増悪の臨床的特徴 ∼特発性肺線維症急性増悪との比較検討∼, 第65回日本リウマチ学会総会・学術集会, Apr. 2021.
71.	Kohjin Murakami, Seidai Satou, Takeshi Imakura, 西村春佳, Naoki Takahashi, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Masahiko Azuma, Hiroshi Nokihara and Yasuhiko Nishioka : 抗線維化薬2剤を切り替えて使用した特発性肺線維症症例の後方視的検討, 第61回日本呼吸器学会学術講演会, Apr. 2021.
72.	近藤健介, Hiroshi Nokihara, Seidai Satou, Atsushi Mitsuhashi, Hiroto Yoneda, Hiroyuki Kozai, Kenji Otsuka and Yasuhiko Nishioka : 非小細胞肺癌に対する免疫チェックポイント阻害剤の予後予測因子の検討, 第61回日本呼吸器学会学術講演会, Apr. 2021.
73.	西村春佳, Seidai Satou, Takeshi Imakura, Kohjin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : ブレオマイシン誘発肺線維症モデルマウスにおけるJAK阻害剤の効果に関する検討, 第61回日本呼吸器学会学術講演会, Apr. 2021.
74.	Naoki Takahashi, Seidai Satou, Takeshi Imakura, Kohjin Murakami, Nobuhito Naito, Kozo Kagawa, Kazuya Koyama, Hiroshi Kawano, Hiroshi Nokihara, 谷川原万顕, 鳥海亙 and Yasuhiko Nishioka : ブレオマイシン誘発肺線維症モデルマウスにおける核酸医薬PK-7010とnintedanibの併用効果の検討, 第61回日本呼吸器学会学術講演会, Apr. 2021.
75.	今倉健, Nobuhito Naito, Yuya Yamashita, 原田紗希, Kozo Kagawa, Hiroto Yoneda, Seidai Satou, Hiroshi Kawano, 長谷加容子, Hiroshi Nokihara and Yasuhiko Nishioka : 当科における成人発症スティル病症例の検討, 第262回徳島医学会学術集会, Mar. 2021.
76.	青井優, Nobuhito Naito, 今倉健, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : Atezolizumab投与後に著明な血小板減少症をきたした1例, 第262回徳島医学会学術集会, Mar. 2021.
77.	美馬正人, Nobuhito Naito, 原田紗希, 今倉健, 山下雄也, 髙橋直希, Seidai Satou, Hiroshi Kawano and Yasuhiko Nishioka : 当科における抗ARS抗体陽性症例の検討, 第31回日本リウマチ学会中国・四国支部学術集会, Dec. 2020.
78.	Yuya Yamashita, Nobuhito Naito, 原田紗希, 今倉健, 髙橋直希, Seidai Satou, Hiroshi Kawano and Yasuhiko Nishioka : ST合剤による無菌性髄膜炎を呈したシェーグレン症候群の一例, 第31回日本リウマチ学会中国・四国支部学術集会, Dec. 2020.
79.	原田紗希, Nobuhito Naito, 岡本悠里, Kozo Kagawa, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 不明熱の精査でMEFV遺伝子解析により診断した家族性地中海熱の1例, 第123回日本内科学会四国地方会, Nov. 2020.
80.	Akane Abe, Nobuhito Naito, Kenji Otsuka, Yukikiyo Kawakami, Shiroh Fujii, Seiji Iwamoto, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 非小細胞肺癌に合併した後天性血友病Aの1例, 第123回日本内科学会四国地方会, Nov. 2020.
81.	Hiroto Yoneda, Nobuhito Naito, Hiroyuki Kozai, Kenji Otsuka, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara, Masahiko Azuma and Yasuhiko Nishioka : 当科における悪性胸膜中皮腫に対するnivolumab投与症例の検討, 第123回日本内科学会四国地方会, Nov. 2020.
82.	折野逸人, Nobuhito Naito, 内藤仁美, 髙橋直希, Hironori Tanaka, Seidai Satou, Hiroshi Kawano, Hisanori Uehara, Hiroshi Nokihara, Tetsuji Takayama and Yasuhiko Nishioka : 肝肺症候群に進展したサルコイドーシスの1例, 第64回日本呼吸器学会中国・四国地方会, Nov. 2020.
83.	磯村祐太, Nobuhito Naito, 山下雄也, Asami Fukuya, Kazuya Koyama, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 当科における胸水貯留を呈した膠原病および類縁疾患症例の検討, 第64回日本呼吸器学会中国・四国地方会, Nov. 2020.
84.	梶本達也, Nobuhito Naito, 内藤仁美, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara, Masahiko Azuma and Yasuhiko Nishioka : 全身性強皮症に伴う間質性肺炎の増悪との鑑別を要した鳥関連過敏性肺炎の1例, 第29回日本呼吸器内視鏡学会中国四国支部会, Nov. 2020.
85.	國重道大, Nobuhito Naito, 原田紗季, 山下雄也, 高橋直希, 美馬正人, Hiroyuki Kozai, Seidai Satou, Hiroshi Kawano, Toshihiko Nishisho, Daisuke Hamada, Hiroshi Nokihara, Tetsuya Matsuura, Koichi Sairyo and Yasuhiko Nishioka : 当科における骨・関節病変を呈した非結核性抗酸菌症の検討, 第71回日本結核・非結核性抗酸菌症学会中国四国支部会, Nov. 2020.
86.	Hiroshi Kawano, Yuya Yamashita, Nobuhito Naito, Seidai Satou, Muneyuki Kadota, Takayuki Ise, Shusuke Yagi, Masataka Sata, Hiroshi Nokihara and Yasuhiko Nishioka : 高安動脈炎による難治性皮膚潰瘍に対してべペルミノゲンペルプラスミド(ヒト肝細胞増殖因子プラスミドベクター)投与が奏効した1例, 第48回日本臨床免疫学会総会, Oct. 2020.
87.	Yasuhiko Nishioka and Seidai Satou : 進行性線維化性フェノタイプの分子病態, 第60回日本呼吸器学会学術講演会(シンポジウム), Sep. 2020.
88.	Yuko Toyoda, Seidai Satou, Kazuya Koyama, Kozo Kagawa, 上甲剛, 江頭玲子, 寺崎泰弘, 蛇澤晶, 萩原弘一, 稲瀬直彦 and Yasuhiko Nishioka : 特発性肺骨化症全国調査(中間報告), 第60回日本呼吸器学会学術講演会, Sep. 2020.
89.	髙橋直希, Seidai Satou, Kazuya Koyama, Kozo Kagawa, Nobuhito Naito, 今倉健, Yuko Toyoda, Hiroshi Kawano, 谷川原万顕, 鳥海亙 and Yasuhiko Nishioka : ブレオマイシン誘発肺線維症モデルマウスにおける核酸医薬PK-7010の抗線維化効果の検討, 第60回日本呼吸器学会学術講演会, Sep. 2020.
90.	Kozo Kagawa, Kazuya Koyama, Seidai Satou, Naoki Takahashi, 西村春佳, Hiroshi Kawano, Yuko Toyoda, Tsutomu Shinohara and Yasuhiko Nishioka : ブレオマイシン肺線維症マウスモデルにおけるLck阻害の抗線維化効果, 第60回日本呼吸器学会学術講演会, Sep. 2020.
91.	Seidai Satou, 森本友樹, 山本卓志, 丸尾朋也, 脇華菜 and Yasuhiko Nishioka : イメージング質量顕微鏡によるニンテダニブの線維性肺組織内局在分布の検討, 第60回日本呼吸器学会学術講演会, Sep. 2020.
92.	Hiroshi Kawano, Nobuhito Naito, 安宅克博, 今倉健, Yuya Yamashita, 高橋直希, Mayo Kondou, Seidai Satou, Yuko Toyoda and Yasuhiko Nishioka : 当院における進行性線維化を伴う膠原病関連間質性肺疾患の検討, 第64回日本リウマチ学会総会・学術集会, Aug. 2020.
93.	Seidai Satou, Kohjin Murakami, Yuko Toyoda, Kazuya Koyama, 西村春佳, Kozo Kagawa, 髙橋直希, Hiroshi Kawano, Masahiko Azuma and Yasuhiko Nishioka : 2剤の抗線維化薬を使用した特発性肺線維症症例の検討, 第117回日本内科学会講演会, Aug. 2020.
94.	平岡栞名, 三井由加里, Hirokazu Miki, Seidai Satou, Momoyo Azuma, 遠藤ふうり, 宮髙紘輔, 辻誠士郎, 桝田志保, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Seiji Fukumoto, Munehide Matsuhisa and Masahiro Abe : 発熱・全身リンパ節腫脹で発症し，リンパ節生検で診断しえた結核性リンパ節炎の一例, 第261回徳島医学会学術集会, Aug. 2020.
95.	青井優, Kozo Kagawa, Nobuhito Naito, Seidai Satou, Hiroshi Kawano, Jinsei Miyoshi, Tomomi Matsuura, Hideya Kashihara, Kouzou Yoshikawa, Yuko Toyoda, Yoshimi Bando, Hiroshi Nokihara, Tetsuji Takayama, Mitsuo Shimada and Yasuhiko Nishioka : 好酸球性多発血管炎性肉芽腫症の治療中に回腸出血をきたし，血管炎との鑑別が困難であったCMV腸炎の1例, 第260回徳島医学会学術集会, Feb. 2020.
96.	安宅克博, Hiroshi Kawano, Takeshi Imakura, Nobuhito Naito, Mayo Kondou, Seidai Satou, Yuko Toyoda and Yasuhiko Nishioka : 蛋白濾出性胃腸症，クリオグロブリン血症を伴ったMCTDの1例, 第30回日本リウマチ学会中国・四国支部学術集会, Dec. 2019.
97.	Nobuhito Naito, Hiroshi Kawano, Takeshi Imakura, Mayo Kondou, Seidai Satou, Yuko Toyoda and Yasuhiko Nishioka : 当科におけるANCA陽性間質性肺炎症例の検討, 第30回日本リウマチ学会中国・四国支部学術集会, Dec. 2019.
98.	石田卓也, Kozo Kagawa, Hiroto Yoneda, Kenji Nishimura, 山本遥平, Seidai Satou, Hiroshi Kawano, Hiroshi Nokihara and Yasuhiko Nishioka : 顕微鏡的多発血管炎の治療中に重症筋無力症クリーゼを発症した1例, 第121回日本内科学会四国地方会, Dec. 2019.
99.	佐古雅宏, Kozo Kagawa, Makoto Tobiume, 高橋直希, Takeshi Imakura, Nobuhito Naito, Hiroyuki Kozai, Seidai Satou, Yuko Toyoda, Hiroshi Nokihara, Masahiko Azuma and Yasuhiko Nishioka : Mycobacterium malmoenseによる肺感染症の2例, 第70回日本結核病学会中国四国支部会, Nov. 2019.
100.	磯村祐太, Kozo Kagawa, Hiroto Yoneda, Hiroshi Nokihara, Kenji Otsuka, Seidai Satou, Makoto Tobiume, Hiroyuki Kozai, Satoshi Sakaguchi, Masahiko Azuma and Yasuhiko Nishioka : 当科における悪性胸膜中皮腫の2次治療の検討, 第62回日本呼吸器学会中国・四国地方会, Nov. 2019.
101.	Kohjin Murakami, Kozo Kagawa, 小山壱也, Masahiko Azuma, Daisuke Matsumoto, Mitsuhiro Tsuboi, Yukikiyo Kawakami, Kazuya Kondo, Seidai Satou, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka : 大量胸水および胸膜腫瘤を契機に診断された甲状腺濾胞癌の一例, 第28回日本呼吸器内視鏡学会中国四国支部会, Nov. 2019.
102.	石田卓也, Kozo Kagawa, Hiroto Yoneda, 坂東紀子, Nobuhito Naito, Hirokazu Ogino, Seidai Satou, Hiroshi Kawano, Kenji Nishimura, 山本遥平, Yuko Toyoda, Hiroshi Nokihara and Yasuhiko Nishioka : 顕微鏡的多発血管炎の治療中に重症筋無力症クリーゼを発症した1例, 第259回徳島医学会学術集会, Aug. 2019.
103.	Kozo Kagawa, 小山壱也, Seidai Satou, Naoki Takahashi, 西村春佳, Nobuhito Naito, Hiroshi Kawano, Yuko Toyoda and Yasuhiko Nishioka : ブレオマイシン肺線維症マウスモデルにおけるLck阻害の抗線維化効果, 第61回日本呼吸器学会中国・四国地方会, Jul. 2019.
104.	近藤健介, Atsuro Saijo, Kozo Kagawa, Kenji Otsuka, Seidai Satou, Hiroto Yoneda, Makoto Tobiume, Hisatsugu Goto, Hiroshi Nokihara and Yasuhiko Nishioka : 末梢血検査値を用いた非小細胞肺癌に対する免疫チェックポイント阻害剤の効果予測因子の検討, 第58回日本肺癌学会中国・四国支部学術集会, Jul. 2019.
105.	安宅克博, Kozo Kagawa, Mayo Kondou, Seidai Satou, Hiroto Yoneda, Hirokazu Ogino, Makoto Tobiume, Hiroyuki Kozai, Kenji Otsuka, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : Nivolumab投与により腹水の著明な減少を認めた悪性胸膜中皮腫の1例, 第58回日本肺癌学会中国・四国支部学術集会, Jul. 2019.
106.	近藤圭大, Kozo Kagawa, Mayo Kondou, Hirokazu Ogino, Makoto Tobiume, Hiroto Yoneda, Kenji Otsuka, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : 当科における局所進行非小細胞肺癌患者に対する化学放射線療法後のDurvalumabによる治療の臨床的検討, 第58回日本肺癌学会中国・四国支部学術集会, Jul. 2019.
107.	内藤仁美, Kozo Kagawa, Mayo Kondou, Seidai Satou, Nobuhito Naito, Hiroshi Kawano, Yuko Toyoda, Masahiko Azuma, Hiroshi Nokihara and Yasuhiko Nishioka : 関節リウマチで治療中に抗MDA5抗体陽性をみとめ，無筋症性皮膚筋炎と診断された間質性肺炎の2例, 第61回日本呼吸器学会中国・四国地方会, Jul. 2019.
108.	Seidai Satou, Yasuhiko Nishioka and Kolb Martin : 線維化肺組織の細胞外基質が線維細胞のmiR-21発現に及ぼす影響の検討, 第18回肺サーファクタント分子病態研究会, Jun. 2019.
109.	Nobuhito Naito, Hiroshi Kawano, Mayo Kondou, Hirokazu Ogino, Seidai Satou, Yuko Toyoda, Hisatsugu Goto and Yasuhiko Nishioka : 間質性肺炎合併関節リウマチに対するJAK阻害薬の使用経験, 第63回日本リウマチ学会総会・学術集会, Apr. 2019.
110.	Seidai Satou, Upagupta Chandak, Yanagihara Toyoshi, Kolb RJ. Martin and Yasuhiko Nishioka : Fibrotic extracellular matrix upregulates pro-fibrotic miRNA expression of fibrocytes, The 59th Annual Meeting of the Japanese Respiratory Society, Apr. 2019.
111.	Hiroyasu Okazaki, Seidai Satou, Shun Morizumi, 小山壱也, Hirohisa Ogawa, Kozo Kagawa, 西村春佳, Chen Yajuan, Yoshinori Aono, Shuichi Abe, Momoyo Azuma, Hisatsugu Goto, Hiroshi Kawano, Yuko Toyoda, Hisanori Uehara, 小路弘行 and Yasuhiko Nishioka : ブレオマイシン肺線維症マウスモデルにおけるWnt/B-カテニン/CBPシグナル阻害薬PRI-724による抗線維化効果の検討, 第59回日本呼吸器学会学術講演会, Apr. 2019.
112.	小山壱也, Nobuhito Naito, Kozo Kagawa, 西村春佳, Seidai Satou, Hiroshi Kawano, Yuko Toyoda, Hisatsugu Goto, Masahiko Azuma and Yasuhiko Nishioka : 関節リウマチ合併間質性肺炎患者の急性呼吸不全の臨床的検討, 第59回日本呼吸器学会学術講演会, Apr. 2019.
113.	小山壱也, Nobuhito Naito, Kozo Kagawa, Mayo Kondou, 西村春佳, Seidai Satou, Hiroshi Kawano, Yuko Toyoda, Masahiko Azuma, Hisatsugu Goto and Yasuhiko Nishioka : マウス肺線維症モデルにおける新規multi-tyrosine kinase inhibitor TAS-115の抗線維化効果の検討, 第258回徳島医学会学術集会, Feb. 2019.
114.	Seidai Satou, Yuko Toyoda, Nobuhito Naitoh, Hiroto Yoneda, Kohzoh Kagawa, Haruka Nishimura, Mayo Kondou, 小山壱也, Hiroshi Kawano, Hisatsugu Goto and Yasuhiko Nishioka : 気管支肺胞洗浄液中fibrocyteにおけるmiR-21発現の疾患別差異に関する検討, 第27回日本呼吸器内視鏡学会中国四国支部会, Dec. 2018.
115.	Yohsuke Kaneko, Mayo Kondou, Naoki Takahashi, Makoto Tobiume, Hirokazu Ogino, Seidai Satou, Hirokazu Miki, Hisatsugu Goto, Masahiro Abe and Yasuhiko Nishioka : 多発小結節影を認めたHIV陽性ニューモシスチス肺炎の1例, 第119回日本内科学会四国地方会, Dec. 2018.
116.	Yuya Yamashita, Hiroshi Kawano, Takeshi Imakura, Nobuhito Naito, Mayo Kondou, Hirokazu Ogino, Seidai Satou, Yuko Toyoda, 後東久嗣 and Yasuhiko Nishioka : TAFRO症候群の1例, 第29回日本リウマチ学会中国・四国支部学術集会, Dec. 2018.
117.	Nobuhito Naitoh, Hiroshi Kawano, Mayo Kondou, Hirokazu Ogino, Seidai Satou, Yuko Toyoda, Hisatsugu Goto and Yasuhiko Nishioka : EBウイルス再活性化を反復した高疾患活動性関節リウマチに対してアバタセプトが有効であった1例, 第29回日本リウマチ学会中国・四国支部学術集会, Nov. 2018.
118.	Mayo Kondou, Hiroki Bandoh, Kozo Kagawa, 西村春佳, 小山壱也, Seidai Satou, Yuko Toyoda, Masahiko Azuma, Hirohisa Ogawa, Hisatsugu Goto and Yasuhiko Nishioka : リゾフォスファチジン酸を標的にしたアレルギー性気道炎症制御についての検討, 第257回徳島医学会学術集会, Aug. 2018.
119.	坂東紀子, Yuko Toyoda, Hiroshi Kawano, Seidai Satou, 小山壱也, 西村春佳, Kozo Kagawa, Nobuhito Naitoh, Masahiko Azuma and Yasuhiko Nishioka : 当科で経験した抗MDA5抗体陽性皮膚筋炎合併間質性肺炎の臨床像の検討, 第59回日本呼吸器学会中国・四国地方会, Jul. 2018.
120.	Toshifumi Tezuka, Hirohisa Ogawa, Mayo Kondoh, Yuko Toyoda, Seidai Satou, Hisatsugu Goto, Jun Kishi, Masahiko Azuma, Masaki Hanibuchi and Yasuhiko Nishioka : ダニ抗原誘導性のアレルギー性気道炎症および気道リモデリングはPAR-2 antagonistの投与により抑制される, 第57回日本呼吸器学会学術講演会, Apr. 2017.
121.	Shun Morizumi, Seidai Satou, Hirokazu Ogino, Koyama Kazuya, Haruka Nishimura, Yuko Toyoda, Hiroshi Kawano and Yasuhiko Nishioka : Inhibition of pan-fibroblast growth factor receptor signaling in bleomycin-induced pulmonary fibrosis in mice, The 57th Annual Meeting of the Japanese Respiratory Society, Apr. 2017.
122.	森住俊, Seidai Satou, Hirokazu Ogino, Hiroshi Kawano, Satoshi Sakaguchi, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi, Masahiko Azuma and Yasuhiko Nishioka : 当院におけるニンテダニブの特発性肺線維症に対する使用経験, 第114回日本内科学会四国地方会, May 2016.
123.	山下雄也, Atsuro Saijo, Seidai Satou, Toshifumi Tezuka, Satoshi Sakaguchi, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi, Masahiko Azuma and Yasuhiko Nishioka : 当院における膠原病合併肺癌の検討, 第114回日本内科学会四国地方会, May 2016.
124.	Yuko Toyoda, Seidai Satou, Jun Kishi, Hiroshi Kawano, 森住俊, 岸昌美, Toshifumi Tezuka, Satoshi Sakaguchi, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 当院における膠原病関連間質性肺炎の急性増悪に関する臨床的検討, 第56回日本呼吸器学会学術講演会, Apr. 2016.
125.	Toshifumi Tezuka, Hirohisa Ogawa, Mayo Kondoh, Masahiko Azuma, Yuko Toyoda, Seidai Satou, Hiroyasu Okazaki, Hiroshi Kawano, Jun Kishi, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : RAS阻害剤 (XRP44X) を用いた喘息モデルマウスにおける検討, 第56回日本呼吸器学会学術講演会, Apr. 2016.
126.	小山広士, Seidai Satou, 近藤真代, Toshifumi Tezuka, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi and Yasuhiko Nishioka : 胸膜炎や心外膜炎を契機に診断された成人Still病の2例, 第252回徳島医学会学術集会, Feb. 2016.
127.	四宮由貴, Seidai Satou, Akio Takezaki, Mayo Kondoh, Terumi Takikura, Satoshi Sakaguchi, Yuko Toyoda, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi and Yasuhiko Nishioka : サルコイドーシス経過観察中に発症した結核性胸膜炎の1例, 第24回日本呼吸器内視鏡学会中国四国支部会, Dec. 2015.
128.	曽我部洋平, Seidai Satou, Atsuro Saijo, Mayuri Nakano, Hiroshi Kawano, Satoshi Sakaguchi, Yuko Toyoda, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi and Yasuhiko Nishioka : 癌性髄膜炎に対しアファチニブが奏効した2例, 第54回日本呼吸器学会中国・四国地方会, Dec. 2015.
129.	Hiroto Yoneda, Seidai Satou, Kohzoh Kagawa, Hirokazu Ogino, Satoshi Sakaguchi, Yuko Toyoda, Momoyo Azuma, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi and Yasuhiko Nishioka : 骨髄異形成症候群に播種性結核症を合併し治療に難渋した一例, 第66回日本結核病学会中国四国支部会, Dec. 2015.
130.	Shun Morizumi, Seidai Satou, Hirokazu Ogino, Mayo Kondoh, Toshifumi Tezuka, Yuko Toyoda, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi and Yasuhiko Nishioka : 当科で施行された胸膜癒着術におけるタルク製剤とOK-432の使用成績の比較, 第113回日本内科学会四国地方会, Dec. 2015.
131.	Mayo Kondoh, Seidai Satou, Toshifumi Tezuka, Yuko Toyoda, Makoto Tobiume, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi and Yasuhiko Nishioka : 胸膜炎・心外膜炎を契機に診断された成人Still病の2例, 第113回日本内科学会四国地方会, Dec. 2015.
132.	山下雄也, Hirokazu Ogino, Jun Kishi, Yuko Toyoda, Shun Morizumi, Mayo Kondoh, Terumi Takikura, Seidai Satou, Hiroshi Kawano, Toshifumi Tezuka, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 強膜炎，ネフローゼ症候群および僧房弁腱索断裂による重症僧房弁閉鎖不全症を呈した全身性エリテマトーデスの1例, 第26回日本リウマチ学会中国・四国支部学術集会, Dec. 2015.
133.	Hirokazu Ogino, 三橋惇志, Hisatsugu Goto, Atsuro Saijo, Seidai Satou, Satoshi Sakaguchi, Toshifumi Tezuka, 倉本卓哉, 田畑祥, Hisanori Uehara, Masaki Hanibuchi and Yasuhiko Nishioka : Sphere形成癌幹細胞様分画のヒト肺癌多臓器転移モデルマウスにおける役割についての解析, 第74回日本癌学会学術総会, Oct. 2015.
134.	梶田敬介, Seidai Satou, Yuko Toyoda, Satoshi Sakaguchi, Toshifumi Tezuka, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : PS不良ALK融合遺伝子陽性の若年者肺腺癌に対しクリゾチニブが奏効した1例, 第251回徳島医学会学術集会, Aug. 2015.
135.	香川耕造, Satoshi Sakaguchi, 塚﨑佑貴, Seidai Satou, 飛梅亮, 米田浩人, 竹﨑彰夫, Toshifumi Tezuka, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 癌性髄膜炎にafatinibが奏効したEGFR exon 18 G718A変異をもつ肺腺癌の1例, 第54回日本肺癌学会中国・四国支部会, Jul. 2015.
136.	Satoshi Sakaguchi, Yuko Toyoda, Toshifumi Tezuka, Akio Takezaki, Mayuri Nakano, Terumi Takikura, Seidai Satou, Hiroyasu Okazaki, Kenji Ohtsuka, Souji Kakiuchi, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi and Yasuhiko Nishioka : 肺胞出血をきたした11症例の検討, 第38回日本呼吸器内視鏡学会学術集会, Jun. 2015.
137.	Mikiko Takei, Mayo Kondo, Seidai Satou, Hiroshi Kawano, Yuko Toyoda, Masaki Hanibuchi, Yasuhiko Nishioka, Hirokazu Miki, Kumiko Tanaka and Tetsuji Takayama : 好酸球性胆管炎を合併した全身性エリテマトーデスの1例, 第112回日本内科学会四国地方会, Jun. 2015.
138.	Yuko Toyoda, Terumi Takikura, Mayo Kondo, Seidai Satou, Ryohiko Ozaki, Jun Kishi, Toshifumi Tezuka, Hiroshi Kawano, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 膠原病に合併した血球貪食性リンパ組織球症の4症例, 第59回日本リウマチ学会総会・学術集会, Apr. 2015.
139.	Seidai Satou, Hisatsugu Goto, Shun Morizumi, Shuichi Abe, Terumi Yoshijima, Hiroyasu Okazaki, Masaki Hanibuchi and Yasuhiko Nishioka : 肺線維芽細胞に対するfibrocyteの作用とnintedanibの抑制効果, 第55回日本呼吸器学会学術講演会, Apr. 2015.
140.	Toshifumi Tezuka, Hirohisa Ogawa, Yuko Toyoda, Akio Takezaki, Seidai Satou, Hiroyasu Okazaki, Terumi Yoshijima, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : Plasminogen Activator Inhibitor-1阻害剤 (IMD-4690) の慢性喘息モデルマウスにおける検討, 第55回日本呼吸器学会学術講演会, Apr. 2015.
141.	Maiko Iwasaka, Seidai Satou, Hirokazu Ogino, Satoshi Sakaguchi, Yuko Toyoda, Mayuri Nakano, Shun Morizumi, Hirohisa Ogawa, Souji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : Idiopathic pleuroparenchymal fibroelastosis (IPPFE) における間質性肺炎マーカーの検討, 第112回日本内科学会講演会, Apr. 2015.
142.	稲垣太造, 荻野広和, Satoshi Sakaguchi, Yuko Toyoda, Mayuri Nakano, Shun Morizumi, Seidai Satou, Hirohisa Ogawa, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : Idiopathic pleuroparenchymal fibroelastosisにおける間質性肺炎マーカーの検討, 第250回徳島医学会学術集会, Feb. 2015.
143.	岩佐あゆみ, Seidai Satou, Satoshi Sakaguchi, Yuko Toyoda, 田島壮一郎, 櫻田巧, Hisatsugu Goto, Souji Kakiuchi, Masaki Hanibuchi and Yasuhiko Nishioka : UGT1A1遺伝子のヘテロ接合体 (6または28) を持つ患者における塩酸イリノテカン投与に関する検討, 第52回日本呼吸器学会中国・四国地方会, Dec. 2014.
144.	Mayo Kondoh, Seidai Satou, Yuko Toyoda, Jun Kishi, Toshifumi Tezuka, 吉嶋輝実, Masami Kishi, Hiroshi Kawano, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 血小板減少を契機として診断された高齢者のSLEの2例, 第25回日本リウマチ学会中国・四国支部学術集会, Dec. 2014.
145.	Shun Morizumi, Seidai Satou, Satoshi Sakaguchi, Yuko Toyoda, Masami Kishi, Hirohisa Ogawa, Souji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : Idiopathic pleuroparenchymal fibroelastosisにおける間質性肺炎マーカーの検討, 第111回日本内科学会四国地方会, Nov. 2014.
146.	Souji Kakiuchi, 大塚憲司, Seidai Satou, Atsuro Saijo, Satoshi Sakaguchi, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 当院における間質性肺炎合併肺癌の治療の現状, 第55回日本肺癌学会学術集会, Nov. 2014.
147.	Motokazu Matsuura, Sayo Ueda, Hiroyuki Ono, Sakiya Yoshimoto, Eriko Shibata, Masanori Tamaki, Taichi Murakami, Kojiro Nagai, Hideharu Abe, Seidai Satou, Jun Kishi, Yasuhiko Nishioka and Toshio Doi : 関節リウマチに対してetanercept投与中に半月体形成性糸球体腎炎を来した1例, 第44回日本腎臓学会西部学術大会, Oct. 2014.
148.	Motokazu Matsuura, Sayo Ueda, Hiroyuki Ono, Sakiya Yoshimoto, Eriko Shibata, Masanori Tamaki, Taichi Murakami, Kojiro Nagai, Hideharu Abe, Seidai Satou, Jun Kishi, Yasuhiko Nishioka and Toshio Doi : 関節リウマチに対してetanercept投与中に半月体形成性糸球体腎炎を来した1例, 第44回日本腎臓学会西部学術大会, Oct. 2014.
149.	山下雄也, 荻野広和, 阿河弘和, 岸昌美, Satoshi Sakaguchi, 吉嶋輝実, Seidai Satou, Souji Kakiuchi, Hisatsugu Goto, Jun Kishi, Masaki Hanibuchi and Yasuhiko Nishioka : 鳥特異的抗体が高値を呈した鳥関連過敏性肺炎の一例, 第249回徳島医学会学術集会, Jul. 2014.
150.	塚﨑佑貴, 大塚憲司, 岸昌美, 近藤真代, 吉嶋輝実, Seidai Satou, 岡埼弘泰, 竹﨑彰夫, Momoyo Azuma, Masaki Hanibuchi, 坂下直美, 福田悠 and Yasuhiko Nishioka : Acute Fibrinous and Organizing Pneumonia (AFOP) の一剖検例, 第51回日本呼吸器学会中国・四国地方会, Jul. 2014.
151.	阿河弘和, Seidai Satou, Mayo Kondoh, 塚﨑佑貴, Toshifumi Tezuka, Yuko Toyoda, Satoshi Sakaguchi, Souji Kakiuchi, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 当科における悪性胸水貯留例に対するタルク製剤の使用経験, 第53回日本肺癌学会中国・四国支部会, Jul. 2014.
152.	尾崎領彦, Yuko Toyoda, Jun Kishi, Katsuhiro Kinoshita, Masami Kishi, Seidai Satou, Souji Kakiuchi, Masaki Hanibuchi and Yasuhiko Nishioka : 左腎動脈閉塞等により結節性多発動脈炎が疑われた血管内膜肉腫の1剖検例, 第110回日本内科学会四国地方会, Jun. 2014.
153.	Seidai Satou, 岸昌美, Katsuhiro Kinoshita, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 血清 SP-D 上昇を認めた Idiopathic pleuroparenchymal fibroelastosis (IPPFE) 症例の検討, 第54回日本呼吸器学会学術講演会, Apr. 2014.
154.	Souji Kakiuchi, 大塚憲司, Seidai Satou, Atsuro Saijo, Satoshi Sakaguchi, Hisatsugu Goto, Masaki Hanibuchi and Yasuhiko Nishioka : 当院における間質性肺炎合併肺癌の治療の現状, 第54回日本呼吸器学会学術講演会, Apr. 2014.
155.	岸昌美, Yoshinori Aono, Momoyo Azuma, Katsuhiro Kinoshita, Seidai Satou, 吉嶋輝実, 竹﨑彰夫 and Yasuhiko Nishioka : PDGFレセプター-α, β阻害抗体のブレオマイシン誘発肺線維症モデルマウスにおける抗線維化効果, 第54回日本呼吸器学会学術講演会, Apr. 2014.
156.	The Trung VAN, Hisatsugu Goto, 倉本卓哉, Souji Kakiuchi, Seidai Satou, The Trung VAN, Atsuro Saijo, 田畑祥, Hirohisa Ogawa, Hisanori Uehara, Shin-ichi Akiyama, Yasuhiko Nishioka, Rae Jo WRIGHT and Saburo Sone : 肺サーファクタント蛋白SP-Aの肺がん進展における機能解析, Journal of Japanese Medical Society for Lung Surfactant and Biological Interface, Vol.43, 32, Oct. 2012. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1570009751236977280 (CiNii: 1570009751236977280)
157.	Makoto Tobiume, Seidai Satou, Yuko Toyoda, Hisatsugu Goto, 多田浩也, Yasuhiko Nishioka and Saburo Sone : 異なるEGFR遺伝子変異を有する多発肺腺癌の一例．, 第19回日本呼吸器内視鏡学会中国四国支部会, Jan. 2011.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

質量分析イメージングによる薬剤性間質性肺炎の病態解析および新規診断法の開発 (Project/Area Number: 24K11366 )
肺がん・中皮腫における新たな抗原提示細胞の同定から革新的複合がん免疫療法への展開 (Project/Area Number: 22H03079 )
細胞外基質による線維細胞のmiR-21発現制御に着目した肺線維症の新規治療法開発 (Project/Area Number: 21K08204 )
The fibrotic extracellular matrix induces release of extracellular vesicles with pro-fibrotic miRNA from fibrocytes (Project/Area Number: 19K17638 )
Development of novel combination immunotherapy against lung cancer and mesothelioma: establishment of immunological basis for clinic (Project/Area Number: 19H03668 )
Fibrocyte分化制御による肺線維症の新規治療戦略への展開 (Project/Area Number: 15K19421 )
Search by Researcher Number (80530899)

Associate Professor : Satou, Seidai

Research

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)